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Abstract 
 
The TAM (TYRO3, AXL, and MERTK) family of receptor tyrosine kinases allow phagocytes to 
engage in the phagocytic removal of apoptotic cells. Although all three members of the TAM 
family are structurally homologous and function in a similar fashion, both human genome-wide 
association studies and knockout mice models have demonstrated that MERTK is the critical 
member of the TAM family for maintaining homeostasis. In this thesis, an evolutionary analysis 
was used to provide insight into the function of MERTK. Selection analysis in primates 
unexpectedly revealed a high degree of recent positive selection in MERTK’s signal peptide and 
transmembrane domain, absent from TYRO3 and AXL. Reconstruction of hominid and primate 
ancestral signal peptides revealed three nonsynonymous mutations in humans, with a G14C 
mutation producing a potential non-B DNA cruciform motif, which may regulate MERTK 
expression. Reconstruction of MERTK’s transmembrane domain determined that humans acquired 
three amino acid substitutions and two insertion/deletion mutations (INDELs) which added four 
amino acids. These new amino acids were largely leucines and isoleucines, and create a new 
interaction motif that increased self-clustering of MERTK. Although we found no significant 
difference among human MERTK and primate- or hominid-ancestral reconstructed signal peptides 
in expression levels or protein trafficking, recent evolutionary changes in MERTK’s 
transmembrane revealed significantly higher self-clustering with human MERTK, and hominid 
ancestral, compared to the reconstructed primate-ancestral transmembrane. This project highlights 
the importance of recent MERTK evolution, which has increased self-clustering. 
Keywords: TAM receptors, MERTK, Efferocytosis, Evolution, Positive Selection 
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Chapter 1: Introduction 
 
TYRO3, AXL, and MERTK (TAM) receptors are a family of receptor tyrosine kinases that play 
essential roles in maintaining homeostasis through the removal of apoptotic cells (ACs). These 
receptors are found in the nervous, vascular, reproductive, and immune systems1. The expression 
of TAM receptors, along with an appropriate integrin co-receptor, imparts an efferocytic capacity 
on a cell2. Like many phagocytic receptors, TAM receptors do not directly bind to their targets, 
and instead engage soluble protein opsonins which act as bridging molecules between the TAM 
receptor and cognate ligands on ACs3–6. Phosphatidylserine (PtdSer) is the primary ligand of TAM 
receptor opsonins, although some TAM opsonins may recognize other lipids on the surface of 
ACs7. The three TAM receptors arose early in metazoan evolution, with MERTK and TYRO3 
evolving as a product of whole genome replication during the divergence of jawed from jawless 
vertebrates, and AXL emerging soon after during the separation of ray-finned and cartilaginous 
fish8. Despite their distant evolutionary origins, all three TAM receptors retain a high degree of 
structural and functional similarity, as well as a modest degree of sequence homology (40-50% 
amino acid homology)9. Although structurally and functionally similar, in both humans and mice, 
MERTK is the most critical of the three family members. Indeed, mutations resulting in a total loss 
of MERTK cause retinitis pigmentosa, a congenital form of blindness characterized by a failure to 
clear retinal pigment epithelia (RPE) in the eye, and with less severe single nucleotide 
polymorphisms (SNPs) in MERTK contributing to a range of inflammatory and autoimmune 
diseases10–13. In contrast, few SNPs in AXL or TYRO3 are associated with human diseases10,14, and 
AXL and TYRO3 knockout mice have a less severe phenotype than MERTK knockout mice15–20. 
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1.1 TAM receptor family structure 
The TAM family members are type I transmembrane glycoproteins, with an extracellular domain 
comprised of tandem immunoglobulin-related domains (Ig) followed by tandem fibronectin type 
III (Fbg) repeats (Figure 1)21,22. While both of these domains are common in many tyrosine kinases 
(TKs), TAM receptors uniquely contain two of each domain. TYRO3 and AXL are comparable in 
size, both around 120 kDa and 890 and 894 amino acids respectively. In contrast, MERTK is 
significantly larger, at ~150-170 kDa and 999 amino acids, mainly due to a larger ectodomain1,9. 
All three TAM receptors, like all receptor tyrosine kinases (RTKs), contain a predicted single-pass 
alpha-helical transmembrane domain. Following the transmembrane domains is a highly 
conserved (>70% identity) intracellular tyrosine kinase belonging to the PKC-like superfamily of 
tyrosine kinases1,23 TAM receptors also contain a unique sequence KW(I/L)A(I/L)ES in the 
catalytic kinase domain of the tyrosine kinase that differs from other RTKs21,22. In MERTK a 
YSGDYY motif has been identified as a major autophosphorylation site, where single tyrosine 
mutations reduce kinase activity from 10 to 100%24. TAM receptors interact with their cognate 
opsonins as dimers, with the carboxy-terminal sex hormone-binding globulin (SHBG) domains on 
dimerized opsonins acting to stabilize the TAM dimer and thus initiating signalling25–28.  
 
1.2 TAM receptor opsonins 
TAM receptors bind to ACs indirectly through use of opsonins such as GAS6 and Protein S 
(PROS). These paralogs are about 80 kDa in size and share 44% amino acid similarity29. Each 
contain a carboxy-terminal SHBG domain with two laminin G domains that bind the Ig domains  
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Figure 1: TAM receptor domains and binding interaction. Homodimers of opsonins GAS6 and 
PROS bind to PtdSer through their Gla domain, while their SHBG domains bind to TAM receptor 
homodimers through their Ig domains. GAS6/PROS and TAM receptors also contain EGF-like 
domains and Fbg domains respectively. TAM receptors contain a predicted single pass alpha helix 
transmembrane domain (TM) and signal through their highly conserved internal kinase domain 
(KD). 
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of TAM receptors, thereby inducing TAM dimerization and kinase activation (Figure 1)25–28. 
Following the SHBG domain are four EGF-related domains and the Gamma-carboxylated 
glutamic acid (Gla) domain on the amino terminus. The Gla domain is rich in glutamic acid 
residues which undergo a vitamin-K dependent post-translation gamma-carboxylation, allowing 
for Ca2+-dependent binding of PtdSer on the AC25–28. Interestingly, the Gla domains also function 
independent of TAM receptors as an anticoagulant in the blood coagulation cascade. Indeed, Pros-
/- mice possess an embryotic lethal phenotype due to exuberant blood coagulation30. However, 
Gas6 knockout mice appear normal, but have delayed coagulation, indicative of a negative 
coregulatory role of GAS631. 
 
PROS and GAS6 function as dimers to bind TAM receptors, and they activate TAM receptor 
signalling following multimerization25–28. Although homodimers of both opsonins have been 
studied, it remains unclear whether the opsonins are capable of heterodimerization, and if so, how 
this affects receptor binding affinities and signalling. Homodimers of GAS6 and PROS display 
different affinities among TAM receptors; GAS6 has been shown to bind all three TAM receptors, 
while PROS only activates TYRO3 and MERTK32. Although GAS6 binds all three TAM 
members, it has a much higher affinity for AXL (Kd = 0.4 nM), then TYRO3 (Kd = 2.7 nM) and 
its lowest affinity is for MERTK (Kd = 29.0 nM)
3. Interestingly, while AXL has the strongest 
affinity for GAS6, MERTK is more readily activated when exposed to GAS6 in the presence of 
PtdSer, highlighting its predmoninant role in AC clearance33. 
 
PROS is abundant in human plasma (300 nM), while GAS6 is present at significantly lower 
concentrations (0.02-0.2 nM)30. Both ligands are produced through autocrine/paracrine signalling 
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from TAM-positive cells including endothelial cells and hepatocytes34–36. Interestingly, GAS6 is 
believed to be entirely bound to a soluble form of AXL, which is cleaved following activation, in 
circulation30. GAS6 and AXL share a unique relationship, as GAS6 is AXL’s sole opsonin and 
binds it with a significantly higher affinity than the other TAM receptors32. In addition, expression 
of GAS6 appears to be dependent on AXL signalling, as GAS6 expression is entirely lost in major 
organs like the spleen, liver and lungs in Axl-/- mice, but not Tyro3-/- and MerTK-/- mice33.  
 
GAS6 and PROS are well characterized opsonins for TAM receptors, but new evidence is 
emerging for three other opsonins: TUBBY, TUBBY-like protein 1 (TULP-1), and Galectin-3 
(Gal-3)5,6,37. These three putative opsonins are unusual in that they are normally restricted to the 
cytosol, with both TUBBY and TULP-1 having known roles as intracellular PtdSer sensors38. 
TUBBY and TULP-1 are normally retained on the cytosolic face of the plasma membrane through 
their interactions with phosphatidylinositol 4,5-biphosphate (PIP2)
38. Following phosphoinositide 
hydrolysis, TUBBY functions by translocating to the nucleus, likely to function as a transcription 
factor for lipid synthesis genes through its NH2-terminal regions
39. Secretion of these opsonins 
does not require cell death, and instead appears to occur via an uncharacterized, ER-independent 
secretion pathway similar to that used by IL-1β40.  
 
TUBBY and TULP-1 are expressed in neural and retinal tissues, but it remains unclear whether 
they are also present in the circulatory system or released at sites of inflammation5,39. Mutations 
in both opsonins have shown their importance in RPE phagocytosis, where deficiencies in either 
opsonin leads to a partial loss of RPE phagocytosis41. TULP-1 activates all three TAM receptors, 
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whereas TUBBY solely activates MERTK. Both bind the receptor(s) with their N-terminal region 
and interact through an unknown ligand on ACs through their C-terminal domain. TULP-1 also 
possesses an essential sequence (K/R(X)1-2KKK) for activation of MERTK on its N-terminus
5. 
Gal-3 is the most recently discovered MERTK-specific opsonin. It is unclear how it binds to 
MERTK, but it does possess a C-terminal carbohydrate binding domain which binds 
glycoproteins. This binding is critical for Gal-3’s function as an effective MERTK bridging 
molecule, as saturation of its lectin domain through addition of lactose reduces its ability to 
facilitate efferocytosis6. Like TUBBY and TULP-1, Gal-3 plays a role in RPE phagocytosis, as 
light exposure causes increased photoreceptor degeneration and a concomitant increase in Gal-3 
expression42. In addition, Gal-3 is a known binding molecule for advanced glycation end products 
– found in Alzheimer’s disease, diabetes, cardiovascular disease, and in aging retinas – indicating 
that it may opsonize ACs and lipoproteins independent of PtdSer43,44.  
 
1.3 TAM receptor family evolution 
TAM receptors are a subfamily within the PK superfamily. As TAM receptors are transmembrane 
proteins that specifically phosphorylate the tyrosine residues, they belong to the subdivision of 
PKs known as receptor tyrosine kinases (RTKs). RTKs all share a common internal C-terminal 
tyrosine kinase domain (TKD), contain a single pass alpha helical transmembrane domain, and 
their signalling cascades are involved in an array of critical processes including embryotic 
development, growth factor signalling, apoptosis, and cell activation and cell differentiation. The 
main difference between the 20 RTK subfamilies lies in their distinct N-terminal domain exposed 
to the cell surface. These domains allow RTK-ligand binding, which in turn produces homo- or 
hetero-receptor dimerization, thus initiating a signalling cascade8,45.  
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The diversity of human and vertebrate RTK’s is due to four whole genome duplications (WGDs) 
that occurred early in vertebrate evolution8. Following these WGDs, genomes returned to a diploid 
state, but retained many of the duplicated genes, resulting in a vast expansion of many gene 
families46. As gene duplications allow for rapidly increased evolutionary change compared to 
singletons, retained RTK duplicates created diverse subfamilies with greatly expanded 
functions47,48. The TAM family members first formed through WGDs, with both MERTK and 
TYRO3 evolving as jawed and jawless vertebrates diverged, and with AXL diverging from TYRO3 
during the separation of ray-finned and cartilaginous fish8. The evidence of TAM receptor 
emergence from WGD is highlighted by their distinct chromosome locations: TYRO3 on 
chromosome 15 (at 15q15), AXL on chromosome 19 (at 19q13.1), and MERTK on chromosome 2 
(at 2q14.1)9. This distribution is consistent with duplication of whole chromosomes, whereas gene 
duplication by errors in homologous repair generate gene copies on the same chromosome, and 
retrotransposition create duplicates lacking introns. Pre-dating TAM receptors, proteins 
resembling TAM receptor opsonins first appeared in genomes of pre-vertebrate urochordates. 
Interestingly, urochordate genomes also contain a TAM-like tyrosine kinase which is linked 
through its transmembrane domain to a TAM-opsonin-like domain, and therefore is likely able to 
directly recognize apoptotic cell PtdSer49. This ancestral gene may represent the ancestor to all 
TAM receptors, although this relationship has not been thoroughly examined.   
 
 
1.4 Biological roles of TAM receptors 
The biological role of TAM receptors was largely delineated following the creation of TAM KO 
mice. PTK KO mice are often nonviable as many PTKs function in embryonic development, thus 
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successful development of single TAM KO mice, as well as double and triple TAM KO, was 
notable35. TAM KO mice have been invaluable in TAM receptor research, with many studies using 
these mice or bone marrow-derived macrophages from these mice, for study. TAM triple knockout 
(TKO) mice appear phenotypically normal for the first three weeks following birth, but thereafter 
develop a degenerative phenotype that is lethal after approximately one year15,16,35,36,50,51. 
Generation of these mice has enabled the elucidation of the biological importance of TAM 
receptors in the male reproductive system, RPE cells, the blood-brain barrier, and in macrophages 
and dendritic cells.   
 
Adult male TAM TKO mice become infertile after five weeks, one week after the onset of sperm 
production, due to the failure to remove apoptotic germ cells produced during spermatogenesis in 
the seminiferous tubules of the testes35. Without removal through efferocytosis, these ACs build-
up and lead to the death of all germ cells in the male reproductive system. Sertoli cells – which 
express all three TAM receptors – are responsible for this function, and without TAM receptor 
expression, efferocytosis is nearly non-existent32,35,52,53. MERTK plays a critical role in germ cell 
removal, as MerTK-/- mice are the only single KO TAM mice to display AC germ cell build-up. 
However, AC germ cell build-up levels are exacerbated with dual MerTK and Tyro3 KO mice, 
resulting in accelerated sterility compared to MerTK single knockouts32.   
 
Similar to male germ cells, TAM receptors play a critical role in RPE phagocytosis. In the retina, 
photoreceptors (PRs) continually grow through the addition of membrane-based segments at the 
base of their multi-segment bodies. As the segments age they are displaced from the cell body, 
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becoming outer segments (OS). During this aging process photodamage accumulates, eventually 
requiring the removal of the OS by RPE cells – expressing TYRO3 and MERTK – which engulf 
damaged distal OS tips that are no longer capable of light detection. Diurnally, the distal OS tip 
displays PtdSer on the surface to allow specific engulfment of this section by RPE cells. This is a 
process unique from efferocytosis as the engulfment is restricted to a portion of the cell, and the 
cell is still viable54,55.  TKO TAM and MerTK-/- mice are born with normal retinae, but are blind 
two months after birth due to extensive death of their PRs, a phenotype not observed in Tyro3 and 
Axl knockouts36,56. In humans, mutations in MERTK, but not TYRO3 or AXL, have also been shown 
to lead to retinitis pigmentosa, further highlighting the importance of MERTK compared to other 
TAM receptors13.  
 
TAM receptors are critical for phagocyte-induced efferocytosis in tissues outside of the eyes and 
testes. In other tissues, TAMs are predominantly expressed by macrophages and dendritic cells, 
and are required to clear the over 100 billion ACs produced daily in a healthy human33. In 
macrophages, MERTK signalling is required for AC clearance, as mice expressing MERTK with 
a truncated kinase domain show a near abolishment of efferocytosis. Interestingly, Axl-/-, Tyro3-/-, 
and Axl-/-Tyro3-/- mice show a 50% reduction in macrophage AC clearance, indicating that they 
play a cooperative role with MERTK57. Although these studies showed a heavy reliance on 
MERTK for AC clearance, recent studies have shown differential expression patterns and 
efferocytosis specialization in macrophages dependent on environmental signals. In tolerogenic 
and anti-inflammatory settings MERTK expression predominates, while inflammatory 
environments induce upregulation of AXL and a concomitant downregulation of MERTK; Anti-
inflammatory macrophage subtype M2c display high levels of MERTK expression, while 
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inflammatory macrophage subtype M1 display high AXL expression33. Bone marrow-derived 
dendritic cells isolated from wild-type mice show high levels of AXL expression, with low levels 
of other TAM receptors. However, setting specific TAM receptor expression is also seen in DCs 
with the same patterns as macrophages. TYRO3 expression is not required for either DC or 
macrophage efferocytosis57. Differential TAM receptor expression highlights the potential 
differential functions for TAM receptors.  
 
1.4.1 TAM signalling 
While incompletely understood, TAM receptor activation drives a RTK signalling cascade 
involving dimerization-induced TKD autophosphorylation and downstream activation of the 
phosphoinositide 3 kinase (PI3K)/AKT pathway58–61. TAM receptor autophosphorylation occurs 
at two sites, within the TKD and in the C-terminal tail. TKD phosphorylation activates the kinase 
domain allowing for phosphorylation of both the C-terminal tail and downstream proteins61. 
Phosphorylation of the C-terminal tail creates a binding site for growth factor receptor-bound 
protein 2 (Grb2), which in turn recruits the p85 adaptor subunit of PI3K, followed by the p110 
kinase subunit which phosphorylates PIP2 to form phosphatidylinositol-3,4,5-triphosphate 
(PIP3)
9,62,63. The production of PIP3 induces the canonical PIP3 signalling cascade, including the 
activation of AKT and downstream activation of AKT substrates such as mTOR, leading to 
numerous downstream processes including proliferation, cell survival, growth and angiogenesis64.  
 
TAM receptors also function as negative regulators of innate immune responses through the 
JAK/STAT pathway34,65. Many cytokines and growth factor receptors lack an intrinsic kinase, and 
instead engage Janus kinases (JAKs) upon receptor dimerization. JAKs autophosphorylate when 
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dimerized, leading to the recruitment and activation of STATs which then dimerize and translocate 
to the nucleus, where they act as transcription factors66. TAMs function as negative regulators in 
this pathway by coupling with INFAR, which in turn induces the expression of suppressor of 
cytokine signalling-1 (SOCS1) and -3 (SOCS3). These inhibitors suppress JAK/STAT signalling 
by binding phosphotyrosines on JAK kinases, or by acting as a pseudo JAK substrate through their 
N-terminal domains, thereby reducing STAT activation by JAKs, leading to decreased production 
of type I IFN67.  
 
1.4.2 Efferocytosis 
Cell turnover is an essential physiological process constantly occurring in the body, with the 
removal of old, damaged, senescent or otherwise unneeded cells mediated via the dual processes 
of apoptotsis – programmed cell death – and efferocytosis, the phagocytic removal of ACs. These 
two processes are responsible for removing more than 100 billion cells daily from the human body, 
but without timely efferocytosis these ACs accumulate, become necrotic and release inflammatory 
molecules with danger associated molecular patterns such as heat-shock proteins and ATP9. 
Efferocytosis, however, is an anti-inflammatory and tolerogenic process which induces the 
secretion of IL-10 and TGFβ68. Defects in efferocytosis have many pathological outcomes, 
including developmental malformations, chronic inflammatory diseases and autoimmunity. The 
primary signal for AC recognition is the exposure of PtdSer on the cell surface. In healthy cells, 
flippases maintain membrane asymmetry, confining PtdSer to the inner leaflet of the plasma 
membrane. However, under apoptotic conditions, scramblases are activated, and flippases 
inactivated, thereby distributing PtdSer to both leaflets of the plasma membrane, thus allowing for 
binding by efferocytic opsonins and receptors69–71.  
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There are an array of efferocytic receptors, which can bind ACs directly or via opsonins. The T 
cell immunoglobulin- and mucin-domain-containing molecule (TIM) family (TIM-1, TIM-3 and 
TIM-4) recognize PtdSer directly, whereas integrins recognize PtdSer indirectly through milk fat 
globule EGF factor 8 (MFG-E8)72–76. Scavenger receptors such as CD36 can also recognize ACs, 
but through oxidized lipids and glycoproteins on AC surfaces77,78. Often, multiple receptors 
cooperate to induce efferocytosis79–81. As an example, in macrophages the scavenger receptor 
CD204 signals through MERTK81; MERTK in-turn depends on integrins such as αvβ5 to complete 
efferocytosis2,79,82. The integrin plays an active role in AC binding, and engages ACs through the 
PtdSer binding opsonin MFG-E8. It should be noted that the requirement for integrins in MERTK-
induced efferocytosis has been shown in HEK293T cells and CS-1 melanoma cells2, but this 
association has yet to be demonstrated in macrophages, and moreover, some in vitro studies have 
observed MERTK-mediated efferocytosis in the absence of MFG-E8/integrin binding of the AC83. 
Whether the dependence of MERTK-mediated efferocytosis on integrins represents a cell-type 
specific phenomenon, or one dependent on the particular efferocytic receptors expressed alongside 
MERTK, has yet to be elucidated. 
 
Although a detailed mechanism for TAM receptor efferocytotic signalling has yet to be 
established, several molecules involved in this mechanism have been identified. As discussed 
above, TAM receptors indirectly bind ACs through opsonins, leading to receptor dimerization and 
autophosphorylation of tyrosine kinases (Figure 2). The co-activation of integrins by MERTK has 
been proposed to involve autophosphorylation of Tyr-867 in MERTK, leading to Src recruitment,  
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Figure 2: TAM receptor signalling pathway. TAM receptor homodimers bind to opsonins GAS6 
and PROS homodimers to activate signalling through the kinase domain. The kinase domains 
activate when the receptor is bound to its opsonin through autophosphorylation of tyrosine kinases, 
which are recognized by Grb2. Grb2 recruits PI3K which in turn phosphorylates PIP2 to promote 
efferocytosis. Upon TAM activation, phospholipase Cγ2 (PLCs) is stimulated, which leads to 
enhanced PKC activity. TAMs may be able to solely activate efferocytosis through PKC activation 
of Rac1, or Rac1 can be activated following Src activation, and cross-talking with αvβ5 through 
FAK. Adapted from ref 84. 
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activation, and Src-mediated phosphorylation of focal adhesion kinase (FAK)61. Phosphorylated 
FAK is recruited to the integrin where it increases the formation of p130cas/CrKII/Dock180 
complex which in turn leads to actin cytoskeleton rearrangement through Ras-related C3 
botulinum toxin substrate 1 (Rac1) to phagocytose ACs2,61. TAM receptors may also signal 
directly to Rac1 through activation of PLC potentially allowing TAM receptors to bypass integrin-
mediated cytoskeletal modeling61. Furthermore, the aforementioned PI3K activation is essential 
for MERTK-dependent phagocytosis, where it likely acts to enhance cytoskeletal rearrangements 
such that large particulates can be engulfed85.  
 
1.5 TAM receptors in infection and disease 
 
1.5.1 Inflammation and autoimmunity 
Efferocytosis is a tolerogenic and anti-inflammatory process that removes potential AC-derived 
autoantigens, thus, TAM receptor deficiencies are unsurprisingly linked to numerous chronic 
inflammatory and autoimmune diseases86,87. TAM TKO and MerTK-/- mice display the most severe 
phenotypes due to increased levels of autoantibodies, accumulation of ACs and secondary necrotic 
cells, and elevated levels of inflammatory cytokines such as TNF-α and IL-115,16,20. These defects 
are more severe in TAM TKO mice, in part because MerTK-/- mice have increased levels of DC 
maturation and antigen cross-presentation, which augments activation of lymphocytes15. Even 
with these defects, both TAM TKO and MerTK-/- mice spontaneously develop clinical symptoms 
similar to systemic lupus erythematosus (SLE)15. Moreover, TAM receptors – mainly MERTK – 
have been linked to rheumatoid arthritis, type II diabetes, atherosclerosis, multiple sclerosis (MS) 
and inflammatory bowel disease in corresponding murine disease models15,17–19,23,88,89. In humans, 
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genome wide association studies have linked MERTK SNPs to MS, and SLE11,90, while 
polymorphisms in both MERTK and TYRO3 have been linked to atherosclerosis10. In addition, 
AXL SNPs have been linked to insulin resistance, obesity and high level of C-reactive protein 
(correlates with risk of developing cardiovascular disease)14. TAM receptor associations with 
inflammatory and autoimmune diseases highlight their role, as well as the predominant role of 
MERTK, in maintaining homeostasis. 
 
1.5.2 TAM receptors as viral targets 
Enveloped viruses – including viruses from the poxviridae, flaviridae, filovirdiae and retroviridae 
families – exploit TAM receptors for immunosuppressive signalling and cell entry34,91. They use 
a form of viral mimicry termed “apoptotic mimicry”, where PtdSer asymmetry is lost in their 
envelopes, leading to PtdSer exposure on the virion surface92. Opsonins then bridge these viruses 
to TAM receptors and signalling is induced. A major innate immune response to viruses is toll-
like receptor-signalling which produces a type I IFN-response; however, TAM receptors can 
inhibit production of type I IFNs through IFNAR-mediated expression of SOCS1 and SOC334. 
Indeed, studies have shown that SOCS1 and SOCS3 mRNA is lower in Ebola-, Marburg virus-, 
and Murine Leukemia virus-infected TAM TKO DCs, and antiviral type I IFN mRNAs are 
augmented, compared to wild-type mice93. Furthermore, TAM kinase signalling is critical for viral 
infections, as mice bearing TAM receptors with non-functional kinase domains have significantly 
reduced levels of infection, although the mechanism resulting in reduced infection remains to be 
elucidated34. Infecting viruses also preferentially interact with specific members of the TAM 
family. TAM TKO DCs have been shown to be highly resistant to West Nile virus and HIV-1 
16 
 
infection, with MerTK-/- DCs displaying similar resistance to infection93. Interestingly, expression 
of AXL has been shown to be increased in patients infected with hepatitis C virus94, and patients 
possessing a favourable SNP in IFNL3 had lower levels of AXL expression in the liver and 
stronger induction following IFN treatment95. The ability to facilitate viral entry and induce anti-
viral immune responses make TAM receptors ideal targets for anti-viral therapeutics. 
 
1.5.3 TAM receptor association with cancer 
Overexpression of all three TAM receptors, as well as GAS6, have been linked to cancer – both in 
regards to tumour development, and to metastasis. Interestingly, although all three receptors have 
been shown to be upregulated in cancer, it is usually never more than one of the TAM receptors 
that is upregulated in a given tumour. TAM receptors increase cell motility and cell-to-cell 
interactions, factors which likely contribute to the association between TAM receptor expression 
and metastasis21,96. The kinase domain is required for these actin-dependent mechanisms, and 
provides additional signalling through AKT and ERK1/2 pathways which in addition to inducing 
motility also promote cell survival60,62,97. Indeed, in studies using an AXL lacking a TKD, cancer 
cell proliferation was decreased and the cancer cells were less invasive. In addition, studies with 
inhibited AXL documented decreased levels of angiogenesis – likely due to decreased AKT 
signalling. Furthermore, some cancers develop mutations within the TAM kinase domain, 
resulting in a constitutively active kinase. This enhances cell survival and proliferation through 
activation of the AKT pathway – indeed, MERTK was initially identified as a proto-oncogene98,99. 
Finally, the upregulation of TAM receptors, and other efferocytic receptors, may act to limit the 
immunogenicity of tumour cells through enabling the uptake of dying cancer cells by neighbouring 
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cells within the tumour, thereby avoiding subsequent uptake by professional antigen presenting 
cells.  
 
As TAM receptor expression increases rates of metastasis, and is associated with poor cancer 
prognoses, it is unsurprising that many research groups are seeking to inhibit TAM receptor 
activation in cancers. TAM receptor research in cancer has mainly focused on AXL, and has led 
to the generation of multiple small molecule inhibitors and anti-AXL monoclonal antibodies, such 
as R428 which are currently in Phase Ib trials and have been shown to reduce cancer metastasis 
and enhance survival in breast cancer models100. MERTK-selective inhibitors – such as UN2025 
– are also being tested101. However, as AXL and MERTK have been shown to be alternately 
expressed in some cancers102, dual AXL and MERTK inhibitors (6g and GSK2606141) may prove 
the more effective cancer drugs103,104. While these inhibitors have been designed to inhibit TAM 
receptor function in cancer, in the future they will be invaluable tools for the study of TAM activity 
in efferocytosis. 
 
1.6 Hypothesis and objectives 
Although TAM receptors are important regulators of homeostasis, as evidenced by their 
association with numerous autoimmune and chronic inflammatory diseases, little work has been 
conducted on their evolution. Thus, we conducted an evolutionary analysis on the TAM receptors, 
and interestingly, noticed two areas in MERTK, but not other TAM receptors, dominated by 
positive selection – the signal peptide and transmembrane domain – as well as a large number of 
conserved regions. Positive selection indicates evolutionary changes, and while rare, it is observed 
most often in immune-related genes, likely indicative of compensatory evolution105–107. In general, 
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signal peptides evolve more slowly than other coding regions in the same gene, but usually display 
an evolutionary pattern consistent with drift. In contrast, transmembrane domains tend to undergo 
strong conservation106,108. While positive selection of signal peptides has been observed in some 
immune-related genes, the biological impact of these changes remains to be elucidated. Thus, the 
identification of positive selection in MERTK’s signal peptide and transmembrane domain led us 
to evaluate the impacts of these changes in MERTK dimerization, expression, protein trafficking, 
and with the intention of evaluating the impact on MERTK-dependent efferocytosis through 
functional assays. Given these evolutionary patterns, and the predominant use of MERTK as a 
source for viral entry and viral induced anti-inflammatory signalling, we hypothesized that the 
positive selection in MERTK’s signal peptide would lead to reduced surface expression, and 
this lower surface MERTK expression would be compensated for by the co-evolution of 
avidity-enhancing self-clustering. 
 
To evaluate this hypothesis, I established three objectives. 1) Reconstruct primate- and hominid-
ancestral signal peptide and transmembrane domains to identify the specific nucleotide and amino 
acid changes which occurred during recent MERTK evolution. 2) Use chimeric MERTK comprised 
of the reconstructed primate and hominid-ancestral signal peptide or transmembrane domain 
inserted into human MERTK to evaluate the biological impact of these changes on MERTK 
trafficking, expression, and self-clustering. 3) Create a heterologous model system to study the 
impact of evolutionary changes in MERTK’s transmembrane domain on efferocytic efficiency and 
receptor signalling.  
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Chapter 2: Materials and methods 
 
2.1 Materials 
HeLa, COS-7 and HEK293T cells were kind gifts from Dr. Jimmy Dikeakos (University of 
Western Ontario), Dr. Sergio Grinstein (Hospital for Sick Children, Toronto), and Dr. Eric Arts 
(University of Western Ontario) respectively. DH5α Esherichia coli. were a generous gift from 
Dr. John McCormick (University of Western Ontario). FcγRIIA-GFP and Tim4-mCherry 
constructs were kind gifts from Dr. Ronald Flannagan, and cobalt transport protein (CbiN)-GFP 
and mRas-RFP were previously cloned in the lab. Roswell Park Memorial Institute (RPMI), 
Hepes-buffered RPMI (HPMI), Dulbecco’s Modified Eagle Medium (DMEM), and Fetal Bovine 
Serum (FBS) were purchased from Wisent (Saint-Jean-Baptiste, Canada), while Trypsin-EDTA 
and antibiotic/antimycotic were purchased from Corning (Manassas, Virginia). #1.5 thickness 
round cover slips and 16% paraformaldehyde (PFA) were purchased from Electron Microscopy 
Supplies (Hatfield, Pennsylvania). Cycloheximide, dexamethasome and rat anti-HA (3F10) were 
purchased from Sigma-Aldrich (Oakville, Canada). GenJet Plus was purchased from Frogga Bio 
(North York, New York). Lympholyte-Poly was purchased from Cedarlane (Burlington, Ontario) 
and all cytokines were purchased from Peprotech (Rocky Hill, New Jersey). Hoechst, permafluor, 
T4 DNA ligase, Phusion DNA polymerase were purchased from Thermo Scientific. Protein A/G 
beads, polystyrene beads, and silica beads were purchased from Bangs Laboratories, Inc. (Fishers, 
Indiana) and lipids from Avanti Polar Lipids, Inc. (Alabaster, Alabama). All opsonins, restriction 
enzymes, goat isotype control and goat anti-mouse MERTK antibody (AF591) were purchased 
from R&D (Minneapolis, MN), while the rabbit anti-human MERTK antibody (D21F11), anti-β1 
integrin (P5D2), and fluorescent secondary antibodies were purchased from Cell Signalling 
Technology (Danvers, Massachusetts), Developmental Studies Hybridoma Bank (Iowa City, 
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Iowa), and Jackson ImmunoResearch Laboratories, Inc. (West Grove, Pennsylvania) respectively.  
Mouse anti-HA (12CA5) was purchased from Santa Cruz (Dallas, Texas). All other chemicals 
were purchased from Canada BioShop (Mississauga, Canada). Matlab software was purchased 
from MathWorks (Natick, Massachusetts). Prism software was purchased from Graphad (La Jolla, 
California). Mega6 Software and ImageJ were downloaded from www.megasoftware.net109 and 
www.imagej.nih.gov/ij/ respectively. 
 
2.2 Generation of phylogenic trees 
Mammalian MERTK sequences were retrieved from the NCBI database and coding sequence 
alignments for mammals and primates were generated with Muscle using default parameters110. 
For phylogenetic analysis, Bayesian (BIC) and Akaike information criterion (AIC) scores for each 
nucleotide substitution model were compared to determine the model used for mammal and 
primate alignments. Phylogenetic analysis of aligned sequences were performed across all reading 
frames using maximum-likelihood with bootstrapping using the GTR and K2 substitution models 
for primate and mammalian MERTK sequence analysis respectively with gamma distribution, as 
determined by BIC and AIC scores. While AXL and TYRO3 phylogenetic analyses used the T92 
and TN93 selection models respectively, both with gamma distribution. The generated mammalian 
phylogenetic tree was annotated in EvolView. All phylogenetic and molecular evolutionary 
analyses were conducted using MEGA6109.  
 
2.3 Selection analysis 
Unaligned TAM primate sequences were imported into the Selecton online server 
(http://selecton.tau.ac.il/)111, and the Homo sapiens sequence was used as a reference sequence for 
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data output. The constructed phylogenetic trees were used to guide alignments. Selection analysis 
was first performed using the Mechanistic Empirical Combination Model (MEC) with 8 
distribution categories and the JTT amino-acid matrix. As a test of significance, MEC likelihood 
and AIC scores were compared against the M8a model (neutral evolution), with lower MEC AIC 
scores indicating significance. Further selection analysis used the M5 model (positive selection), 
comparing AIC scores with the M7 model (neutral evolution). A comparison between the 
MEC/M8a and M5/M7 AIC scores confirmed MEC as the model of best fit by maximum-
likelihood. Ka/Ks values were used to score amino acid positions for significance, with confidence 
intervals (CI) generated through Selecton. Strong evidence for positive selection was indicated by 
scores of Ka/Ks > 1.5 with CI lower bounds greater than 1, while probable positive selection was 
indicated by CI lower bounds below 1. Strong evidence for purifying selection was indicated by 
Ka/Ks < 0.5 with CI upper bound below 1, while probable purifying selection indicated by CI 
upper bounds greater than 1. Neutral evolution was defined as amino acid positions with Ka/Ks 
values between 0.5 and 1.5, or with large CIs. Selecton data was then imported into MATLAB and 
a custom-written script used to calculate Ka/Ks values averaged over 10 neighboring residues. 
 
2.4 Prediction of ancestral MERTK sequences 
Reconstruction of the ancestral Hominidae and primate MERTK sequence was performed using 
MEGA6109. Nucleotide alignments and phylogenic trees of the Hominidae and Primate MERTK 
sequences, generated above, were imported into MEGA6 and the ancestral sequences predicted a 
maximum-likelihood approach and the K2 evolutionary model. 
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2.5 Hydrophobicity and isoelectric point analysis 
To analyze any biochemical changes in the reconstructed primate and hominid-ancestral MERTK 
signal peptides and transmembrane domains were imported into ExPASy ProtScale and Compute 
PI/Mw and hydrophobicity and isoelectric points calculated.  
 
2.6 Mouse and human MERTK synthesis and mutagenesis 
Due to failure to detect heterologous mouse MERTK expression using the pIRES-EGFP Mer 
(Addgene), we cloned mouse MERTK-GFP was cloned into pEGFP-N1 by digesting mouse 
MERTK from pIRES-EGFP Mer and pEGFP-N1 using BamHI and BglII for 1 h at 37°C, gel 
purifying using a 1% TAE/agarose gel and PCR purification kit, and ligating using T4 DNA ligase. 
The endogenous MERTK stop codon was removed to create a MERTK-GFP fusion protein by 
amplifying the vector using Mouse-FWD and Mouse-REV 5’ phosphorylated primers using 
Phusion DNA polymerase, 36 cycles with an annealing temperature of 60°C and 8 min elongation 
at 72°C (Table 1). The PCR product was DpnI treated for 1 h at 37°C to degrade template DNA 
and gel purified. The purified construct was ligated using T4 DNA ligase, transformed into DH5α 
E. coli, and plated onto 100 µg/mL kanamycin containing LB plates. Clones were sequenced to 
ensure removal of stop codon. 
 
As conventional cloning of human MERTK is not possible due to the presence of multiple motifs 
recognized by bacteria as recombination and phage integration sites, combined with an unusually 
high G/C content (63%), we used the OptimumGene codon-optimization algorithm (GenScript) to 
remove secondary DNA structure, reduce GC content and optimize codon usage (Appendix 1) and 
had the gene synthesized and subcloned into pcDNA3.1(+) (GenScript). An extracellular HA tag  
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Table 1: Primers and synthetic DNA elements used for vector construction. 
Primer/DNA Sequence 
Mouse-FWD 
Mouse-REV 
5’ Phos–ACGGATCCACCGGTCG 
5’ Phos–TGAGGAACCTTCTGAGACTTCAAGACTAC 
HA-FWD 
5’ Phos–
GGCGTAGTCAGGCACGTCGTAAGGATAGTCGGTCTGCAGGCTTCCG 
HA-REV 5’ Phos–CACACACCACTGCTGTCACTG 
SigPep-FWD GAGGAGGCTAAGCCATACCCCCTGTTTCCT 
SigPep-REV GGTGGCAAGCTTAAGTTTAAACGCTAGCCA 
TM-FWD AAATTTGGGAATGCTTTCACTGAGGAAGAC 
TM-REV GTTTCCTGGTGCAGGTGTGCTTGAAGGGGC 
SC-GFP-FWD GCGTTTAAACTTAAGCTTGCCACCATG 
SC-GFP-REV CATGGTGGCGACCGGTCTCATCAGCACCTCGGACCCCT 
CD8α-SigPep* 
TGGCTAGCGTTTAAACTTAAGCTTGCCACCATGGCCTTACCAGTGACC
GCCTTGCTCCTGCCGCTAGCCTTGCTGCTCCACGCCGCCAGGCCGGAG
GCAAGGGAAGAGGAGGCTAAGCCATACCCCCTGTTTCCT 
Human-SigPep* 
TGGCTAGCGTTTAAACTTAAGCTTGCCACCATGGGGCCGGCCCCGCTG
CCGCTGCTGCTGGGCCTCTTCCTCCCCGCGCTCTGGCGTAGAGCTATCA
CTGAGGCAAGGGAAGAGGAGGCTAAGCCATACCCCCTGTTTCCT 
Hominid-
SigPep* 
TGGCTAGCGTTTAAACTTAAGCTTGCCACCATGGGGCCGGCCCCGCTG
CCGCTGCTGCTGGGCCTCTTCCTCCCCGCGCTCTGGAGTAGAGCTATC
ACTGAGGCAAGGGAAGAGGAGGCTAAGCCATACCCCCTGTTTCCT 
Primate-SigPep* 
TGGCTAGCGTTTAAACTTAAGCTTGCCACCATGGGGCCGGCCCGGCTG
CCGCTGCTGCTGGGCCTCTTCCTCCCCGCGCTCTGGAGTAGAGCTATC
ACCGAGGCAAGGGAAGAGGAGGCTAAGCCATACCCCCTGTTTCCT 
Hominid-TM* 
GCCCCTTCAAGCACACCTGCACCAGGAAACGCAGATCCTGTGCTCATC
ATCTTTGGCTGCTTTTGTGGATTTATTTTGATTGGGTTGGTTTTATACAT
CTCCTTGGCCATCAGAAAAAGAGTCCAGGAGACAAAATTTGGGAATG
CTTTCACTGAGGAAGAC 
Primate-TM* 
GCCCCTTCAAGCACACCTGCACCAGGAAACACAGATCCTGTGCTCATC
ATCTTTGGCTGCTTTTGTGGATTTATTTTGGTTTTATATATCTTGGCCAT
CAGAAAAAGAGTCCAGGAGACAAAATTTGGGAATGCTTTCACTGAGG
AAGAC 
5’ Phos = 5’ phosphorylated PCR primer 
* = double-stranded synthesized DNA 
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was added by linearizing the codon-optimized MERTK vector using the HA-FWD/HA-REV 5’ 
phosphorylated primers for PCR (Table 1). PCR was conducted using Phusion DNA polymerase, 
36 cycles with an annealing temperature of 63°C and 8 minutes elongation at 72°C. The PCR 
product was treated with DpnI at 37°C for 1 h to degrade the template and gel purified using a 1% 
TAE/agarose gel and PCR purification kit. The purified linearized construct was then 
recircularized with T4 DNA ligase, transformed into DH5α E. coli, and clones were selected on 
LB agar plates containing 100 µg/mL ampicillin. Successful insertion of the HA tag was confirmed 
by DNA sequencing. This HA-tagged vector and Gibson assembly was used for assembly of all 
subsequent MERTK constructs117. Briefly, the signal peptide and transmembrane domains were 
replaced by linearizing the HA-MERTK construct with PCR using primers flanking the signal 
peptide (SigPep-FWD/ SigPep-FWD) or transmembrane domain (TM-FWD/TM-REV, Table 1), 
using the same PCR cycle and purification protocol as above. The linearized vector was then mixed 
at a 1:5 molar ratio of vector:insert in Gibson assembly117 master mix with synthesized double-
stranded DNA constructs containing 20 bp regions of homology flanking the signal peptide 
(CD8α-SigPep, Human-SigPep, Hominid-SigPep, Primate-SigPep, Table 1) or transmembrane 
domain (Hominid-TM or Primate-TM, Table 1) sequence. The reaction was incubated at 50°C for 
30 min, then transformed into DH5α E. coli and positive clones identified as described above. 
Where GFP tagged version of the vector were required, the constructs generated above were 
subcloned into pEGFP-N1 by PCR amplifying the modified MERTK gene with the SC-GFP-
FWD/SC-GFP-REV primers (Table 1) using Phusion polymerase, 35 cycles, 63°C annealing 
temperature and a 3 min elongation at 72°C. The resulting PCR product was gel purified, and 
inserted into pEGFP-N1 by digesting the PCR product and vector with HindIII and AgeI and 
ligating the fragments together using T4 DNA ligase. 
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2.7 Cell Culture and transfection 
HeLa cells were maintained in RPMI plus 10% FBS and COS-7 and HEK293T cells were 
maintained in DMEM plus 10% FBS. Cells were split upon reaching 80% confluency by washing 
once with phosphate buffered saline (PBS: 0.9% NaCl, 10mM Na2HPO4, 2 mM KH2PO4, pH 7.4) 
followed by a 5 min incubation in trypsin-EDTA and resuspension in either RPMI or DMEM plus 
10% FBS. For imaging, #1.5 thickness 18 mm diameter coverslips were first rinsed in 100% 
ethanol, deprotonated for ~12 h in 1M HCl at 50–60°C with intermittent agitation, rinsed with 
100% ethanol and dried. The coverslips were then placed into the wells of a 12-well tissue culture 
plate, 1 ml of RPMI or DMEM + 10% FBS added, and 100 μL of the cell suspension added drop-
wise to each well. For immunoblot experiments, 300 μL of the cell suspension was added dropwise 
to wells without coverslips. 12- 24 h later the cells were transfected with the desired construct 
following manufacturer’s protocol. Briefly, for each well two tubes of 38 μl serum-free DMEM 
were prepared and 1 μg of DNA added to one tube and 2 μl of GenJet Plus added to the second 
tube. Both tubes were vortexed briefly, the contents combined, and the mixture incubated for 15 
min. The DNA:GenJet Plus complexes were then added drop-wise to the well and incubated 18-
24 h. 
 
2.8 Primary macrophage preparation 
Human blood was collected into heparin, in approval of Western University’s Health Sciences 
Research Ethic Board and in compliance with the Tri-Council Policy Statement on human research 
(Ethics approval attached as Appendix 2), from healthy adult donors and monocytes isolated using 
Lympholyte-poly according to manufacturer’s protocol. Briefly, 5 mL of human blood was layered 
over 5 mL of Lympholyte-poly and centrifuged for 35 min at 300 x g. The monocyte layer was 
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removed using a transfer pipette and the cells washed using 50 mL of PBS and then centrifuged 
for 8 min at 300 x g. The pellet was resuspended in 300 µL of 37°C serum-free RPMI per desired 
well of a 12-well plate. The cell suspension was then pipetted onto sterile 18 mm glass coverslips 
previously placed into the wells of a 12-well plates. Cells were incubated for 1 h at 37°C with 5% 
CO2 to allow monocytes to adhere to glass coverslips and non-adherent cells removed with three 
gentle washes with PBS, 1 mL of RPMI + 10% FBS and 1:100 antibiotic/antimycotic (10,000 
U/mL penicillin, 10 mg/mL streptomycin and 25 μg/mL Amphotericin B) was then added, 
supplemented with cytokines for macrophage sub-type differentiation (M0, M2 and M2c: 10 
ng/mL M-CSF; M1: 20 ng/mL GM-CSF). Following a 5 day incubation at 37°C with 5% CO2, 
cells were washed three times with PBS and media replaced with RPMI + 10% FBS with 
antibiotic/antimycotic along with the appropriate cytokines to complete macrophage 
differentiation (M0: 10 ng/mL M-CSF, M1: 20 ng/mL GM-CSF, 100 ng/mL IFN-γ, and 250 
µg/mL LPS, M2: 10 ng/mL MCS-F and 10 ng/mL IL-4, M2c: 10 ng/mL M-CSF + 100 nM 
dexamethasome). Macrophages were incubated for another 2 days at 37°C with 5% CO2 prior to 
use. 
 
2.9 Microscopy 
All experiments, save the oligomerization assays, used a Leica DMI6000B microscope equipped 
with a 100×/1.40NA objective, photometrics Evolve-512 delta EM-CCD camera and Chroma 
Sedat Quad filter set running Leica LAX software, with samples prepared as described below. The 
oligomerization assays were imaged using a Leica SR Ground-State Depletion microscope 
equipped with a 100×/1.43 NA TIRF objective, plus an addition 1.6× optical magnifier for a total 
of 160× magnification, 125 mw–250 mW imaging lasers (488, 555 and 647 nm) and a 30 mW 
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backpumping laser (405 nm) running Leica Ground-State Depletion Microscopy (GSDM) 
software. Experiment-specific microscopy procedures are described below. 
 
2.10 Immunostaining 
Transfected cells or primary macrophages were washed with PBS and fixed for 15 min with 4% 
PFA in PBS at room temperature. Cells were washed three times with PBS and 1 mL of 0.1% 
triton-x-100 in PBS added for 10 min for internal epitope detections only. Cells were blocked for 
1 h using 5% skim milk in PBS and stained for 1 h using 1:100 primary antibody (anti-human 
MERTK, anti-mouse MERTK, anti-β1 integrin or mouse anti-HA) in blocking buffer. Cells were 
washed with PBS three times and stained using 1:1000 fluorescently tagged secondary Fab 
fragment antibodies. Lastly, cells were washed with PBS three times and if required, incubated in 
1:20,000 Hoechst in PBS for 5 min where applicable. After a final PBS wash, coverslips were 
mounted on glass microscope slides using permafluor and imaged using a Leica DMI6000B 
microscope described.  
 
2.11 Immunoblots and coomassie stains 
Cells were seeded onto 6-well plates, and transfected as previously described for 12-well plates. 
18 h after transfection cells were lysed using Lammelli buffer (0.1% 2-Mercaptoethanol, 0.0005% 
Bromophenol blue, 10% glycerol, 2% SDS, 63 mM Tris-HCl, pH 6.8) plus protease inhibitor 
cocktail. Samples were boiled for 5 min, cooled, and separated using a 10% SDS-PAGE gel at 
150V for 2 h. For coomassie stains, gels were fixed (50% methanol, 10% glacial acetic acid, 40% 
ddH2O) for 30 min, stained with coomassie blue staining solution (0.1% Coomassie Brilliant Blue, 
50% methanol, 10% glacial acetic acid, 40% ddH2O) for 2 h, and destained for 24 h (5% methanol, 
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7.5% glacial acetic acid, 87.5% ddH2O). Lastly, coomassie gels were imaged using a BioRad 
GelDoc EZ imager. For immunoblots, samples were transferred to nitrocellulose membranes at 
4°C for 2 h at 80V, and the membrane blocked with TBST (137 mM NaCl, 2.7 mM KCl, 19 mM 
Tris-HCl, 0.1% Tween-20, pH 7.4) plus 5% skim milk powder for 2 h at room temperature. The 
blots were then incubated with 1:100 rat-anti-HA in TBST + 5% skim milk powder for 2 h, washed 
3 × 10 min with TBST, incubated with 1:1,000 Alexa800-lableled donkey-anti-rat (in TBST + 5% 
skim milk powder) and washed a final 3 × 10 min with TBST. Blots were imaged using a LI-COR 
Odyssey Model 9120.  
 
2.12 Protein trafficking assay 
HeLas were seeded onto µ-Slide 8 wells with a glass bottom and transfected at 80% confluency 
using Fugene HD at 2:0.75 transfection reagent to DNA (µL:µg) according to manufacturer’s 
protocol. Transfected cells were washed three times using 10°C PBS and incubated with 1:100 
mouse anti-HA in serum-free RPMI for 20 min at 10°C to label surface MERTK. Cells were 
washed three times using 10°C PBS and incubated with 50 µg/mL cycloheximide in serum-free 
RPMI with 1:500 donkey anti-mouse 647 for 20 min at 10°C. Cells were washed 3 times in 10°C 
PBS and subsequently imaged in 37°C serum-free RPMI with 50 μg/mL cycloheximide. The wells 
were placed onto a heated/CO2 perfused live-cell piezoelectric stage of a Leica DMI6000B 
microscope described. The position of 10-15 cells were marked using the stage controller and time-
lapse videos of MERTK membrane trafficking captured (5 min/frame, 60 min duration). The 
plasmalamella of each cell was identified by the 647 staining (e.g. cell-surface MERTK). This 
mask was then applied to the GFP channel (total MERTK) and trafficking quantified as the rate of 
increase in GFP intensity within the 647 mask relative to the initial time point.  
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2.13 Protein expression analysis 
HeLa cells were transfected at a 1:3 ratio of mRas-RFP (internal transfection control) and HA-
MERTK-GFP codon-optimized, human or primate or hominid ancestral hybrid constructs. 
Samples were analyzed using widefield microscopy or flow cytometry (using a BD FACS Canto 
II Flow Cytometer) and expression quantified using mean fluorescence intensity (MFI) relative to 
internal control mRas-RFP using ImageJ or FlowJo respectively. For the immunoblot analysis of 
protein expression, HeLa cells were transfected with 1 μg of a 1:30 ratio mixture of the desired 
MERTK construct and HA-tagged CD93. Lysates were obtained and immunoblot conducted as 
described above. MERTK expression was quantified as integrated density ratio between the HA-
CD93 and MERTK bands using ImageJ software. For flow cytometry, cells were trypsinized for 
5 min at 37°C for 5 min, and trypsin was inactivated by RPMI + 10% FBS. Cells were centrifuged 
for 1 min at 6,500 x g, washed three times with PBS, fixed for 10 min using 4% PFA in PBS and 
washed in PBS prior to analysis.  
 
2.14 Oligomerization assay 
Super-resolution GSDM was used to assess oligomerization of GFP-tagged MERTK. HeLa cells 
were transfected with GFP-tagged MERTK and fixed for 20 min at room temperature using 4% 
paraformaldehyde in PBS. The cells were washed 3 times in PBS and then permeabilized using 
PBS + 5% BSA and 0.01% saponin. The fixed and permeabilized samples were then mounted on 
depression slides with the depressions filled with imaging buffer (PFA + 100 mM Cysteamine). 
Once mounted the coverslips were sealed using Twinsil and imaged. The GFP color channel was 
subjected to a depletion period where the sample was excited at maximum intensity until less than 
120 active fluorophores were present in each image. The laser intensity was then reduced to 20% 
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of maximum and the sample imaged at 100 fps for 20,000 to 30,000 frames with the backpumping 
laser intensity increased over time to maintain 50-120 active fluorophores/frame. The resulting 
molecule position files were exported, filtered to remove any molecules detected with a precision 
>20 nm, and to ensure equal sampling of all images, reconstructed using our previously published 
method such that reconstruction ceased when image autocorrelation reached 0.990112. 4 cells per 
condition were imaged in each experiment. Self-clustering was assessed using both spatial 
apposition assays and the radial distribution function, using our custom-written MIiSR software 
for analysis112,113.   
 
2.15 Synthetic efferocytic target preparation 
For antibody-coated bead assays, 2 µg of antibody (goat anti-MERTK, goat IgG, human IgG, Fab 
antibodies) were rotated in 100 µL of PBS with 10 µL of polystyrene beads or protein A/G beads 
for 30 min at room temperature. PtdSer and phosphatidylcholine (PtdChol) beads were prepared 
by combining 10 µL of silica beads with 145 µL or 114 µL of phosphatidylcholine respectively 
with 84 µL of phosphatidylserine for apoptotic mimics only and 4 µL of biotinylated-
phosphatidylethanolamine (biotin-PE)114. Coated silica beads were then dried by nitrogen gas. 
Antibody coated beads and PtdSer/PtdChol beads were washed twice in 500 µL PBS. Beads were 
centrifuged at 4,500 x g for 1 min and resuspended in 200 µL of serum-free RPMI. Opsonized 
PtdSer/PC beads were prepared for each well by rotating 3 µL of bead solution with 5 µL of 
recombinant GAS6 and/or 10 µL of MFG-E8 in a total of 50 µL PBS or 50 µL of human serum 
overnight at 4°C under constant rotation and washed in PBS. 
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2.16 Efferocytosis assays 
1 mL of 37°C serum-free RPMI with 5 µL antibody-coated beads, 3 µL PtdSer/PC beads or whole 
mix of opsonized PtdSer/PC bead solution was added to each well of a 12-well plate containing 
primary human macrophages or transfected cells. Samples were spun down at 300 x g for 1 min 
and incubated for 20 min at 37°C with 5% CO2. Cells were washed three times with PBS and 1 
mL of 37°C serum-free RPMI added per well. Samples were incubated for 40 min at 37°C with 
5% CO2 and then washed three times with PBS. External beads were labelled using 1:500 
streptavidin-Alexa647 in PBS with 1:20,000 Hoechst for 5 min and washed three times with PBS 
prior to fixing for 15 min with 4% PFA, mounting on microscope slides and imaging using 
widefield microscopy. Images were exported to ImageJ and efferocytic index quantified by 
counting the total number of internalized beads (unstained) and dividing by total number of 
transfected cells.  
 
2.17 Statistical analysis 
Unless otherwise noted one-way ANOVAs with Tukey correction was used for analysis. All 
statistical analyses were conducted using GraphPad Prism software. 
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Chapter 3: Results 
 
3.1 Patterns of recent TAM receptor evolution 
The three members of the TAM family – TYRO3, AXL and MERTK – share a common secondary 
structure consisting of an amino-terminal signal peptide followed by tandem Ig, tandem Fbg, a 
transmembrane domain and terminating in a intracellular tyrosine kinase21,22. By analyzing the 
rates of non-synonymous (Ka) versus synonymous (Ks) codon replacement, residues under 
purifying (Ka/Ks < 0.5) and positive (Ka/Ks > 1.5) selection can be detected and compared to their 
position in the shared TAM structure in order to identify conserved functional regions versus non-
critical regions undergoing unconstrained amino acid substitutions (0.5 < Ka/Ks < 1.5, neutral 
evolution/drift). Ka/Ks analysis was performed using evolutionary trees constructed using all 
available primate TYRO3, AXL and MERTK sequences (Figure 3-5). The evolution of TYRO3 in 
primates has been dominated by neutral evolution, with some conservation present in the kinase 
domain (Figure 5A, 6A). AXL is largely conserved, with only ~10% of the gene displaying non-
conservative evolution (Figure 5A, 6B). In marked contrast, MERTK displays regions of strong 
conservation with two large islands of positive selection and minimal drift (Figure 5A, 6C). At the 
level of whole gene evolution, Z-tests and Fisher’s Exact Tests demonstrated that both AXL and 
TYRO3 have undergone a pattern of evolution consistent with drift (neutral evolution) between 
most tested species (Appendix 3AB & 5AB), whereas, MERTK displays a pattern of whole-gene 
conservation (negative selection) (Appendix 3AB & 4AB). Consistent with these observations, 
during primate evolution AXL and TYRO3 have undergone a smaller degree of evolutionary 
divergence than MERTK (Figure 5B-D); indeed, negligible divergence has occurred in AXL and 
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Figure 3: Mammalian evolutionary tree for MERTK. Maximum-likelihood evolutionary tree 
of MERTK, produced using all available mammalian MERTK sequences in the NCBI database. 
Branches indicate the degree of evolutionary divergence, numbers at branch-points indicate 
bootstrap values. 
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Figure 4: Full primate trees for evolutionary analysis of TYRO3, AXL and MERTK. 
Maximum-likelihood evolutionary trees of TYRO3 (A), AXL (B) and MERTK (C), produced using 
all available primate MERTK sequences in the NCBI database. Scales indicate the degree of 
evolutionary divergence, numbers at branch-points indicate bootstrap values. 
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Figure 5: Recent evolution of TYRO3, AXL and MERTK. A) Identification of regions of positive 
and purifying selection by Ka/Ks analysis. Ka/Ks values, averaged over 10 neighboring amino 
acids, are plotted. Ka/Ks > 1.5 indicate positive selection, Ka/Ks < 0.5 indicate purifying selection 
(horizontal dotted lines). Major structural domains are indicated by colored shading, a generalized 
domain diagram is illustrated at the bottom of the figure. SP = signal peptide, Ig = immunoglobulin 
domain, Fbg = fibrinogen-like domain, TM = transmembrane domain, Kinase = tyrosine kinase 
domain. B-D) Maximum-likelihood evolutionary trees of TYRO3 (B), AXL(C) and MERTK (D) 
containing representative members of the hominini (H. sapiens, P. troglodytes and P. paniscus, 
orange), the apes (hominini plus G. gorilla and P. abelii, green), old-world monkeys (P. Anubis 
and C. sabaeus, blue) and new-world monkeys (C. jaccus and S. boliviensis, red). Scales indicate 
the degree of evolutionary divergence, numbers at branch-points indicate bootstrap values.  
 
 
37 
 
 
38 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Per-residue Ka/Ks scores of TAM receptors. Ka/Ks values, mapped against the 
human TYRO3 (A), AXL (B) and MERTK (C) protein sequences. Scores of 1-2 (yellow) indicate 
positive selection with Ka/Ks values above 1.5, and purifying selection is represented by scores of 
6-7 (purple) with Ka/Ks values below 0.5.  
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TYRO3 in the hominini lineage (humans and chimpanzees), and only modest divergence occurred 
between the Hominini, Gorillini and Ponginae lineages (Figure 5BC). In marked contrast, MERTK 
has undergone continued divergence in Hominini, with the degree of divergence observed between 
the Pan  and Homo  branches of the Hominini equal to or greater than that observed in TYRO3 and 
AXL between the Hominini and Gorillini/Ponginae linages (Figure 5D). The presence of adaptive 
evolution and whole-gene selection in MERTK led us to further investigate the impact of MERTK 
evolution on its function. 
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3.2 Recent MERTK evolution  
The higher degree of divergence in MERTK, combined with the presence of two regions of intense 
adaptive (positive) selection, led us to characterize the impact of the recent evolution on MERTK 
function. The first positively-selected region, comprised of amino acids 1 to 21, contains the 
MERTK signal peptide plus an additional residue to include the signal peptide cleavage site 
(Figure 5A, 6C). The second positively selected region contained the transmembrane domain 
bordered by 7 extracellular and 5 intracellular membrane-proximal residues. Using MERTK 
sequences from all available primate species (Figure 4C) and a maximum likelihood approach, the 
hominid-ancestral and primate-ancestral sequences for the signal peptide were reconstructed 
(Figure 7). While all residues of the signal peptide, as well as some proximal residues, have 
undergone positive selection within the primate clade, two mutations have become fixed during 
the differentiation of hominids from primates; the first (G14C) resulting in an arginine-to-proline 
substitution (R5P), and the second (C69T) resulting in a synonymous threonine mutation in a 
neutrally evolving region following the signal peptide cleavage site (T23T, Figures 7AB). The 
G14C mutation resulted in a decrease in the polarity of the hominid signal peptide (Table 2), 
potentially altering the efficacy of signal peptide recognition or rate of MERTK trafficking through 
the ER/Golgi (Figure 7B). A third mutation became fixed as humans differentiated from the other 
hominids (A55C), substituting an arginine for a serine (S20R, Figures 7AB), restoring the polarity 
of the human signal peptide to that observed in the primate ancestral sequence (Table 2). In 
humans, the signal peptide regions of the MERTK mRNA is highly GC-rich (75% GC), which can 
be indicative of the presence of non-B DNA motifs, structures which can create genetic instability 
and regulate gene expression through altering supercoiling or binding of regulatory proteins such 
as transcription factors115,116 .  
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Figure 7: Reconstruction of recent evolution in the MERTK signal peptide and 
transmembrane domain. A) Alignments of the human, hominid-ancestral and primate-ancestral 
signal peptide DNA sequence. The signal peptide cleavage point is indicated by the vertical arrow. 
B) Alignments of the human, hominid-ancestral and primate-ancestral signal peptide protein 
sequences. The signal peptide cleavage point is indicated by the vertical arrow. C) Location of 
non-B DNA motifs and SNP’s in the MERTK signal peptide. Tandem GCT repeats are indicated 
by horizontal arrows, the signal peptide cleavage point is indicated by the vertical arrow. D) DNA 
alignments of the human, hominid-ancestral and primate-ancestral transmembrane domain and 
membrane-proximal regions. E) Amino acid alignments of the human, hominid-ancestral and 
primate-ancestral transmembrane domain and membrane-proximal regions. Horizontal line 
indicates the transmembrane domain. Sequences were reconstructed from four hominids (Homo 
sapiens, Pan troglodytes, Gorilla gorilla, and Pongo abelii), four old world monkeys (Chlorocebus 
sabaeus, Macaca mulatta, Macaca fascicularis, and Papio anubis), and two new world monkeys 
(Saimiri bolviensis, and Nomascus leucogenys) using a maximum-likelihood approach. 
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Table 2: Biochemical characteristics of the human, hominid-ancestral and primate-ancestral 
MERTK signal peptide (residues 1-27) and transmembrane domains (residues 499-532). 
Clade Domain pI* Hydrophobicity** 
Human 
Signal Peptide 10.61 0.51 
Transmembrane 8.92 1.38 
Hominid 
Signal Peptide 7.07 0.64 
Transmembrane 8.92 1.37 
Primate 
Signal Peptide 10.61 0.54 
Transmembrane 7.72 1.23 
*Mono-isotopic isoelectric point 
**Hydrophobicity index117 
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Analysis of the reconstructed MERTK signal peptide sequences revealed that the human, hominid 
and primate signal peptides contain a triplet GCT direct repeat (base pairs 20-29, Figure 7C); 
sequences which can form slipped hairpin motifs. The G14C mutation that arose as hominids 
diverged from primates produced a cruciform motif spanning base pairs 3-14, a structure found in 
both hominids and humans (Figure 7C). 
 
Similar to MERTK’s signal peptide evolution, MERTK’s transmembrane domain has undergone 
positive selection leading to amino acid changes. Additionally, small INDELs in the 
transmembrane domain have occurred throughout the primate tree, with two insertions occurring 
during the divergence of hominids from primates (Figure 7D). These insertions lengthened the 
MERTK transmembrane domain from a 17 residue domain in the ancestral primate to a 21 residue 
domain in hominids. In addition, three mutations have become fixed in the human lineage. The 
first (A1495G) occurred during the divergence of hominids from primates, resulting in a threonine 
to alanine substitution (T499A, Figure 7DE). The second mutation also occurred during 
primate/hominid divergence, resulting in a silent mutation to the I521 residue (T1560C, Figure 
5DE). The final mutation (G1552A) became fixed during the divergence of humans from hominids 
and substituted isoleucine for valine (V518I, Figure 7DE). The mutations occurring during the 
divergence of humans from hominids did not significantly affect the isoelectric point or 
hydrophobicity of the MERTK transmembrane domain (Table 2); however, the insertions which 
occurred during the divergence of hominids from primates significantly increased the 
hydrophobicity of the transmembrane domain (Figure 7E). No non-B motifs were found in the 
transmembrane region of MERTK. 
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3.3 MERTK signal peptide evolution has not altered protein 
expression or trafficking 
To determine if the evolution of the MERTK signal peptide altered the efficacy of MERTK 
trafficking from the Endoplasmic Reticulum (ER) and Golgi to the cell surface, we synthesized a 
codon-optimized version of MERTK lacking any regulatory motifs, thus minimizing any effects 
non-B motifs and tRNA availability on our analyses (See Appendix 1 for the DNA sequence). 
Next, Gibson assembly118 was used to replace amino acids 1-26 of the optimized MERTK with the 
equivalent portion of the human, reconstructed hominid or reconstructed primate MERTK. 
Constructs were transfected into HeLa cells and expression confirmed by immunostain and 
immunoblot (Figure 8). These constructs enabled us to test the effect signal peptide variation on 
protein expression and trafficking through the ER/Golgi, independent of any effects incurred by 
evolution elsewhere in MERTK. Using cycloheximide to block further MERTK translation, and 
fluorescence microscopy, MERTK trafficking from the ER/Golgi to the cell surface was 
quantified, with no significant difference in protein trafficking rate among the human, primate and 
hominid hybrid-ancestral MERTK observed, suggesting that recent evolution in MERTK’s signal 
peptide has not affected protein trafficking effciency (Figure 9).  
 
In addition to altering ER/Golgi trafficking, the evolution of a cruciform motif containing the start 
codon of the hominid and human signal peptide may alter the expression level of MERTK. In 
addition to the hominid- and primate-ancestral constructs, the codon-optimized MERTK was used 
for analysis where all non-B DNA motifs are removed to specifically evaluate any non-B DNA 
effects on expression. Protein expression in HeLa cells co-tranfected with MERTK-constructs 
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Figure 8: Human HA-MERTK-GFP and modified ancestral signal peptides are ectopically 
expressed in HeLa cells. HeLa cells were transfected with constructs containing human MERTK-
GFP or modified human MERTK with reconstructed hominid or primate ancestral signal peptides. 
A) Transfected HeLa cells were immunostained using mouse anti-HA and donkey anti-mouse 647 
with a Hoechst counterstain. Scale bars represent 10 µm. B) MERTK expression was further 
detected through immunoblots using rat anti-HA and donkey anti-rat IR800 antibodies. CbiN was 
used as a negative control. Data re representative of three independent experiments. 
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Figure 9: Evolution in MERTK signal peptide has no significant impact on protein 
trafficking. HeLa cells transfected with constructs containing human HA-MERTK-GFP modified 
to remove potential non-B DNA (codon-optimized) or to contain reconstructed hominid or primate 
ancestral signal peptide domains were surface labelled with anti-HA antibody fluorescently 
labelled secondary antibody. Cells were treated with cycloheximide to halt protein transport and 
protein trafficking measured from time-lapse micrographs as the MFI of total MERTK expression 
divided by surface MERTK expression, and normalized to t = 0. Results are presented as 
normalized MFI over time (A) and as the slope of the protein trafficking plots as quantified by 
linear regressions (B). Data are expressed as +/- SEM, ANOVA with Tukey Correction. Data are 
representative of four independent experiments. 
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and mRas-RFP (internal transfection/expression control) was analyzed using widefield 
microscopy. Hominid-ancestral, but not primate-ancestral, signal peptide MERTK was expressed 
at significantly higher levels than human MERTK (Figure 10). The difference between human and 
hominid-ancestral signal peptides is an A55C transversion leading to an alanine to arginine change 
in the amino acid sequence, which appears to significantly reduce expression. As this expression 
assay is highly dependent on the plane in which the image is captured and is prone to CCD-camera 
noise artefacts when quantifying poorly expressing proteins such as MERTK from our vectors, we 
used flow cytometry to validate these results using the same vectors expressed in the same cell 
type. The flow cytometry analysis showed no significant difference among constructs (Figure 11). 
Because these two fluorescence-dependent assays did not agree, I analyzed whole cell expression 
of the MERTK constructs using immunoblotting. This would bypass all issues regarding labelling 
efficiency and detector noise. Moreover, the low level of MERTK expression observed in all 
constructs, despite the use of a high-expression CMV promoter, suggested that MERTK may be 
readily turned over; perhaps more quickly than the maturation time of the GFP tag (~30 min), 
precluding its detection by fluorescent, but not immunological, technqiues. In place of mRas-RFP, 
HA-tagged human CD93 (a transmembrane protein) was used as a transfection/expression control, 
as both the MERTK and HA-CD93 constructs are expressed off of the same vector (pEGFP-N1) 
via a CMV promotor, and thus this mixture should provide equal transcription initiation of both 
constructs. Immunoblot analyses revealed no significant difference in protein expression among 
the MERTK constructs, indicating that the recent evolution in the signal peptide had no impact on 
MERTK expression and processing in the ER/Golgi (Figure 12). A limitation of these methods is 
that MERTK expression is driven by the CMV promoter, and as such, any impacts of these 
promoter-proximal mutations to endogenous MERTK promoter cannot be measured. 
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Figure 10: Hominid ancestral MERTK signal peptide has augmented expression compared 
to primate ancestral and human signal peptides. HeLa cells co-transfected with constructs 
containing human MERTK-GFP or modified human MERTK with reconstructed hominid or 
primate ancestral signal peptide domains and mRas-RFP as an internal transfection control. 
Expression of both markers was imaged with epifluorescence microscopy (A) and quantified as 
the MFI of MERTK-GFP normalized to mRas-RFP (B). Images are representative of a minimum 
of 60 cells imaged per condition. Scale bars represent 10 µm. Data are expressed as +/- SEM from 
three independent experiments, ANOVA with Tukey Correction. 
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Figure 11: Flow cytometry shows no significant difference in protein expression between 
human and ancestral MERTK. HeLa cells co-transfected with constructs containing human 
MERTK-GFP or modified human MERTK with reconstructed hominid or primate ancestral signal 
peptide domains and mRas-RFP as an internal transfection control. A) Representative GFP 
histogram of control cells (blue) and MERTK-GFP cells (red). B) Expression of both markers was 
quantified by flow cytometry and normalized to mRas-RFP and normalized to human MERTK. 
Data are expressed as +/- SEM from three independent experiments with 5,000 cells counted per 
condition, ANOVA with Tukey Correction. 
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Figure 12: Immunoblots show no significant difference in whole protein expression between 
human and ancestral MERTK. HeLa cells co-transfected with constructs containing human 
MERTK-GFP or modified human MERTK with reconstructed hominid or primate ancestral signal 
peptide domains and HA-CD93 as an internal transfection control. A) Representative immunoblot 
from three independent experiments. Data are presented as integrated fluorescent intensities of the 
240 kDa MERTK-GFP band normalized to HA-CD93 (B). Data are expressed as +/- SEM, 
ANOVA with Tukey Correction. 
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3.4 MERTK transmembrane evolution has increased self-
clustering 
While no apparent phenotype was observed for the signal peptide, the addition of leucines to the 
transmembrane domain during the divergence of hominids from primates (Figure 7E) may indicate 
the development of protein-protein interaction motifs which can act to enhance protein 
dimerization119, and therefore we assessed the possibility that MERTK evolution may have altered 
MERTK self-clustering or interactions with other transmembrane proteins. To determine the 
impact of evolution on the MERTK transmembrane domain, the transmembrane region of the 
codon-optimized MERTK described above was replaced with the equivalent portion of the human, 
reconstructed hominid or reconstructed primate MERTK transmembrane domain. The resulting 
GFP fusion proteins were expressed in HeLa cells, with expression and trafficking to the cell 
surface verified by immunoblotting and immunostaining respectively (Figure 13). Next, cells were 
imaged using super-resolution GSDM microscopy at a resolution of 20 nm, and self-clustering 
assessed by radial distribution function analysis (Figure 14). Primate, hominid and human MERTK 
all formed micro-clusters on the plasmalamella; however, the proportion of MERTK undergoing 
clustering and cluster size was dramatically increased in humans and hominids compared to 
primates. Indeed, primate MERTK clusters averaged <40 nm in diameter, whereas human and 
hominid MERTK formed clusters averaging 100 nm in diameter, with humans trending towards a 
larger portion of clustered MERTK than hominids (Figure 14BC). The size of the primate clusters 
is consistent with homodimers, while the larger hominid and human clusters indicate multimeric 
complexes. Furthermore, in silico analysis of human and reconstructed hominid- and primate-
ancestral transmembrane domains, conducted by our collaborators Dr. Jimmy Dikeakos and 
Brennan Dirk, revealed that while all three transmembranes are predicted to be helical, the human 
and hominid transmembrane domains became slightly elongated as they diverged from the shared 
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Figure 13: Human HA-MERTK-GFP and modified with ancestral transmembrane domains 
are ectopically expressed in HeLa cells. HeLa cells were transfected with constructs containing 
human HA-MERTK-GFP or modified human HA-MERTK-GFP bearing reconstructed hominid or 
primate ancestral transmembrane. A) Confirmation of MERTK surface expression in transfected 
HeLa cells. Total MERTK was detected by the MERTK-intrinsic GFP, while cell-surface MERTK 
was immunostained using an anti-HA antibody. Scale bars represent 10 µm. B) Immunoblots 
confirming MERTK expression, with approximately equal express of all three constructs observed. 
CbiN was used as a negative control. Data are representative of three independent experiments.  
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Figure 14: Evolution in MERTK intermolecular interactions driven by transmembrane 
domain evolution. HeLa cells transfected with constructs containing human MERTK-GFP 
modified to contain the hominid or primate ancestral transmembrane domain were quantified for 
self-clustering. A) TIRF and super-resolution GSDM images of MERTK transmembrane domain 
constructs in the basolateral membrane. Boxes in the TIRF image indicate the 5μm x 5µm region 
shown in the GSDM image, scale bars are 1 µm. B) Quantification of MERTK clustering by the 
radial distribution function (G(r)). C) Clustering of MERTK transmembrane domain constructs, 
expressed as the area under the G(r) curve, normalized to the degree of clustering observed in the 
human construct. A is representative of, and B-C quantify data from three independent 
experiments, four replicates per experiment. Data are expressed as mean (B) or mean +/- SEM (C), 
* = p < 0.05, ANOVA with Tukey Correction. 
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primate ancestor, and moreover, the leucines and isoleucines added to the transmembrane domain 
during this divergence are positioned largely on one facet of the transmembrane domain, 
potentially creating a new protein interaction site (Appendix 5 and 6). Taken together, these results 
suggest that recent MERTK transmembrane evolution has increased MERTK clustering, via the 
evolution of a new hydrophobic interaction facet within the MERTK transmembrane helix. The 
role of this increased clustering remains to be elucidated, but may be indicative of new protein-
protein interactions, or of increased avidity-enhancing MERTK self-clustering. 
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3.6 Development of a model to study MERTK-dependent 
efferocytosis 
To evaluate the impact of MERTK clustering and the necessity of integrins as co-receptors in 
MERTK-mediated efferocytosis, we required a robust and reproducible efferocytosis assay which 
would allow quantification of MERTK-specific efferocytosis. To avoid confounding factors such 
as other efferocytic receptors, non-macrophage cell lines and ligand-specific opsonins or ligands 
were used. To this effect, a mammalian expression vector containing GFP-tagged mouse MerTK 
was created and ectopically expressed in COS-7 cells (Figure 15). MERTK-specific antibody 
coated polystyrene beads were fed to MerTK-transfected COS-7 cells to induce efferocytosis. We 
found that MerTK-transfected, but not CbiN-GFP transfected control cells, internalized 
polystyrene beads coated with MerTK-activating antibodies (Figure 16). However, this uptake was 
nonspecific, as beads coated with isotype control antibodies were also internalized by MerTK 
transfected cells (Figure 16). This non-specific uptake of isotype control beads suggested that the 
antibody preparation may be contaminated by MERTK opsonins. As such, we tested antibodies 
for purity using a commassie stain but found no evidence of opsonin contaminants that may explain 
activation of MERTK (Figure 17). Upon further testing we found that while MERTK internalizes 
both Fab and full length antibodies (Figure 18), internalization was not detected with protein A 
beads coated with anti-MERTK or isotype control antibodies (Figure 19). It is unclear whether this 
was due to non-specific interactions, or if MERTK binds antibodies via a region in the Fab portion 
that is masked by protein A binding. As we could not determine what was inducing MERTK 
internalization with antibody-coated beads, an alternate approach using beads coated in purified 
MERTK-opsonins was assessed. 
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Figure 15: Mouse MERTK is heterologously expressed in COS-7 cells. COS-7 cells were 
transfected with a pEGFP-N1 vector containing MerTK and immunostained for surface expression 
using a goat anti-MERTK antibody (top row) or a goat isotype control antibody (bottom row)  and 
subsequently fluorescently labelled using Cy3 anti-goat secondary antibody. Cells were 
counterstained with Hoechst 33342 to label nuclei. Arrow demarcates receptor accumulation at the 
membrane. Images are representative of three independent experiments. Scale bars represent 10 
µm. 
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Figure 16: COS-7 MerTK-transfectants uptake antibody-coated beads. COS-7 cells were 
transfected with vectors containing MerTK-GFP, FcγRIIA-GFP or CbiN-GFP and fed polystyrene 
beads coated in 2 µg of goat anti-MERTK, goat isotype control or human isotype control 
antibodies. A) Representative image of anti-MERTK coated bead internalization by MerTK-
transfectants, arrows denote an internalized bead and scale bars represent 10 µm B) Average 
number of internalized beads per cell from MerTK, FcyRIIA or CbiN transfected cells exposed to 
antibody coated beads (n=20). Data are presented as mean ± SEM from one independent 
experiment. 
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Figure 17: Coommassie blue stain of antibodies reveal no opsonin contamination. Purified 
goat anti-MERTK, goat isotype control and human IgG antibodies were run through an acrylamide 
gel under reducing conditions and stained using coommassie blue protein stain. Only bands 
corresponding to antibody heavy chain (50 kDa) and antibody light chain (23 kDa) were observed.  
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Figure 18: COS-7 MerTK-transfectants uptake Fab and full length IgG. COS-7 cells were 
transfected with vectors containing MerTK-GFP and fed polystyrene beads coated in full length 
goat IgG or fluorescent-tagged goat Fab fragments. External whole goat IgG was labelled using 
fluorescently-labelled secondary antibodies. Representative images are of goat IgG or goat Fab 
fragment coated bead internalization by MerTK-transfectants. Images are representative of one 
independent experiment. Scale bars represent 10 µm and arrows note representative internalized 
beads. 
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Figure 19: COS-7 MerTK-transfectants do not uptake IgG-coated protein A beads. COS-7 
cells were transfected with vectors containing MerTK-GFP or FcγIIA-GFP and fed polystyrene 
beads coated in goat anti-MERTK, goat isotype control or human IgG. Representative images are 
of MerTK-GFP transfectants fed goat anti-MERTK or goat isotype control coated protein A beads 
and FcγRIIA-GFP fed human IgG coated protein A beads.  External beads were labelled with 
appropriate secondary antibodies. Images are representative of one independent experiment. Scale 
bars represent 10 µm. 
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In our second model, efferocytic targets comprised of 3 µm diameter glass beads coated in a 
mixture that mimics the plasma membrane of ACs (19.8% PtdSer, 80% PtdChol, and 0.2% biotin-
PE) were generated, opsonized with GAS6, and their uptake by mouse MerTK-transfected COS-7 
cells was quantified. Non-internalized beads were stained with streptavidin, which binds the 
exposed biotin-PE on non-internalized beads, and the cells were imaged. We found that MerTK-
GFP-transfected COS-7 cells readily internalized PtdSer-beads opsonized with recombinant 
murine GAS6 (Figure 20). However, non-opsonized PtdSer-beads and GAS6 opsonized 
phosphatidylcholine beads (PC-beads) were rarely internalized by MerTK-GFP transfectants, 
demonstrating that this system is specific to MERTK and that both GAS6 and PtdSer are required 
for MERTK-dependent efferocytosis (Figure 20AB). We confirmed that this system is MerTK-
specific by repeating these experiments using COS-7 cells expressing a different membrane 
protein (CbiN), which displayed background levels of internalization when fed GAS6 opsonized 
PtdSer-beads (Figure 20AB). The efferocytic index of all conditions were calculated and 
demonstrated a marked increase in efferocytosis for MerTK-GFP transfectants fed GAS6 
opsonized PtdSer-beads (Figure 20B). 
 
Shortly after developing the above method we discovered the high degree of divergence among 
MERTK primates (Figure 4C, 5D), and therefore decided that it would be critical for future 
experiments to recapitulate this model system using human MERTK in a human cell line 
(HEK293T cells). HEK293T cells were transfected with a codon-optimized MERTK in 
pcDNA3.1(+) and expression confirmed by immunostaining (Figure 21). For these assays, 
HEK293T cells were co-transfected with CbiN-GFP for visualization and fed PtdSer-beads coated 
in GAS6 with or without MFG-E8. Although MERTK more readily internalized beads coated in  
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Figure 20: COS-7 MerTK-transfectants uptake GAS6 opsonized PtdSer-silica beads. COS-7 
cells were transfected with plasmids containing either MerTK-GFP or CbiN-GFP (negative 
control) and fed silica beads coated in either a mix of PtdSer, PtdChol and biotin-PE or PtdChol 
and biotin-PE. Following coating with lipids, beads were either opsonized in recombinant murine 
GAS6 or left non-opsonized. External beads were labelled with streptavidin-647 to differentiate 
them from internalized beads and nuclei stained with Hoechst. A) Images are representative of a 
minimum of 50 cells per condition. MerTK-GFP transfectants fed GAS6 opsonized PtdSer-beads 
readily internalized beads. White arrow demarcates exemplary internalized bead. As negative 
controls, MerTK-GFP transfected cells were fed non-opsonized PtdSer-beads or PtdChol-coated 
beads opsonized in GAS6. CbiN-GFP transfected cells were fed GAS6 opsonized PtdSer-beads as 
a negative control for MERTK. The average number of internalized beads per cell was determined 
for each condition (B). Error bars represent ± SEM from one independent experiment. Scale bars 
represent 10 µm. 
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Figure 21: Human MERTK is heterologously expressed in HEK293T cells. HEK 293T cells 
were co-transfected with pCDNA3.1-MERTK and CbiN-GFP into and detected through 
immunostaining using an internally targeted anti-MERTK antibody and fluorescent secondary 
antibody. Images are representative of three independent experiments. Scale bar represents 10 µm. 
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GAS6 alone, the efferocytic index was unexpectedly low (Figure 22). Moreover, poor 
internalization was observed with our positive control (TIM-4), which normally would induce the 
uptake of 5-10 fold more beads than observed in these experiments, suggesting that there is an 
issue with our lot of HEK293T cells or the efferocytic targets (Figure 22)80. Due to time constraints 
it was not possible to recapitulate this experiment with new HEK293T cells or efferocytic targets 
prior to thesis submission.  
 
Although transfected cell lines provide an ideal system to study MERTK-dependent efferocytosis 
in isolation, it is important to verify key results in a more biologically relevant system such as 
primary human macrophages. To this end, we conducted a preliminary analysis by evaluating the 
efferocytic capacity of M0, M1, M2 and M2c polarized human PBMC-derived macrophages using 
human serum-coated PtdSer-beads. We found that M0 and M2c primary human macrophages 
displayed the highest level of efferocytosis capacity, which are both shown to highly express 
MERTK14 (Figure 23). While not tested in this thesis, siRNA, small molecule inhibitors, or 
blocking antibodies to MERTK and other TAM receptors could be used to assess their role in 
efferocytosis in the endogenous environment of primary human macrophages. 
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Figure 22: MERTK transfected HEK293T cells do not internalize opsonin-coated PtdSer-
beads. HEK293T cells were transfected with plasmids containing either MERTK with CbiN-GFP, 
CbiN-GFP alone (negative control), or Tim4-mCherry (positive control) and fed silica beads 
coated in either a mix of PtdSer, PtdChol and biotin-PE or PtdChol and biotin-PE. Following 
coating with lipids, beads were either opsonized in recombinant GAS6 with or without MFG-E8. 
External beads were labelled with streptavidin-647 to differentiate them from internalized beads 
and nuclei stained with Hoechst. A) Representative images are displayed for each condition with 
arrows demonstrating representative internalized beads. Scale bars represent 10 µm. B) average 
efferocytic indexes calculated from two independent experiments with a minimum of 100 cells 
counted per condition. Error bars represent ± SEM. 
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Figure 23: Efferocytosis of human serum opsonized PtdSer and PC beads by primary human 
macrophages. Representative images of M0, M1, M2 and M2c polarized macrophages fed silica 
beads containing 79.8% PtdChol, 20% PtdSer, 0.1% biotin‐PE coated in human serum (A). 
Macrophages were immunostained for β1 integrin, counterstained using Hoechst and external 
beads labelled using streptavidin-647. Arrows demarcate representative internalized beads. Scale 
bars represent 10 µm. B) Efferocytic index of M0, M1, M2 and M2c‐polarized macrophages. 
Representative data from one independent experiment which is plotted as interquartile range ± 
minimum/maximum, minimum of 60 cells/condition. PC = beads containing 99.9% PtdChol + 
0.1% biotin‐PE, PS = beads containing 79.9% PtdChol + 20% PtdSer + 0.1% biotin‐PE. 
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Chapter 4: Discussion 
 
4.1 Rational for thesis 
TAM receptors play a critical role in maintaining homeostasis, with MERTK playing the 
predominant role120. The differential roles of TAM receptors is likely a product of their 
independent evolutionary histories, a characteristic of the TAM receptors which has not previously 
been investigated. Thus, using an evolutionary approach, we investigated the impact of recent 
evolution on the TAM family, and performed a detailed biochemical assessment of this evolution 
on MERTK function. We found numerous areas of conservation in MERTK as well as two areas 
of strong positive selection: the signal peptide and the transmembrane domain. Positive selection 
in humans is relatively rare, and the biological implications for these changes often remains 
unclear121,122. As such, we set out to evaluate the functional relevance of the changes in MERTK’s 
signal peptide and transmembrane domain through use of in vitro studies using chimeric MERTK 
ancestral proteins with reconstructed primate- or hominid-ancestral signal peptides or 
transmembrane domains in place of human MERTK.  
 
4.2 Hypothesis and aims 
Our initial characterization of the TAM receptors determined that only MERTK had undergone 
significant adaptive evolution, with much of this evolution confined to the signal peptide and 
transmembrane domain. Given these observations, and previous observations that many enveloped 
viruses enhance infectivity or gain cell entry via TAM receptors92, we hypothesized that the 
positive selection in MERTK’s signal peptide would lead to reduced surface expression, and 
this lower surface MERTK expression would be compensated for by the co-evolution of 
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avidity-enhancing self-clustering. Our first aim was to reconstruct the primate- and hominid-
ancestral signal peptide and transmembrane domains to identify specific nucleotide and residue 
changes in these regions. The second aim was to use create expression vectors containing chimeric 
human MERTK with either the reconstructed primate or hominid signal peptide or transmembrane 
domain for biological analysis. These chimeric proteins were to be used to test for expression level 
and protein trafficking differences in ancestral signal peptides, and the ability to self-cluster in the 
ancestral transmembrane domains. In our third aim, we wanted to create a reproducible in vitro 
assay in which to study MERTK-dependent efferocytosis, allowing for a comparison of how 
evolutionary changes in the transmembrane domain may have influenced efferocytosis capacity. 
Our data indicates that this hypothesis is partially correct – while we did not observe the decrease 
in MERTK expression we predicted, we did observe an increase in MERTK self-clustering, 
consistent with an increase in MERTK avidity and/or the formation of new MERTK/co-receptor 
interactions. 
 
4.3 MERTK signal peptide evolution 
Positive selection in humans is a relatively rare occurrence, and progress on understanding positive 
selection is mostly limited to the types of genes that are likely to undergo positive selection. In 
humans, positive selection is most often observed in immune-related genes, and genes involved in 
olfaction, sperm development and skin pigmentation107,123–125. In addition, likely target genes are 
those where the protein is expressed at low levels and involved in a signalling cascade122,126. These 
factors make TAM receptors likely targets for positive selection; however, MERTK is the only 
TAM receptor that demonstrated positive selection. This difference may highlight preferential 
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binding of MERTK over other TAM receptors by enveloped viruses, leading to antagonistic 
coevolution.  
 
Signal peptides generally evolve at a slower rate than other coding regions, and moreover, tend to 
be under stabilizing selection106,127,128. This relatively slow rate of change, which is otherwise 
neutral, is a product of the minimal biochemical attributes required of most signal peptides – ie. 
polar or neutral amino acids surrounding a somewhat hydrophobic core106. As such, signal peptides 
are relatively free to evolve, so long as the amino acid substitutions maintain this overall 
biochemical characteristic, hence the slow but otherwise neutral evolution typically observed in 
signal peptides. A marked exception to this pattern is found in a number of immune-related genes, 
where signal peptides – and to a lesser degree, the mature protein – evolve faster than average and 
display modest-to-strong positive selection106. Included among these positively-selected signal 
peptides is MERTK, as identified in this thesis, as well as IFN-γ105. However, like in this thesis, no 
biological effect of the evolution of the signal peptide of IFN-γ could be determined. They, and 
we, propose that the observed evolution of these signal peptides is likely due to antagonistic co-
evolution, wherein immune-related proteins are driven to rapidly evolve in response to a 
pathogen105. Indeed, this would be consistent with the parasitism of TAM receptors by enveloped 
viruses, with mutations in MERTK’s signal peptide potentially acting to reduce cell-surface 
expression, thereby reducing viral binding sites. Regardless, the trend of accelerated evolution in 
immune-related signal peptides, in MERTK and other genes, warrants further investigation.  
 
At this time, we have no clear indication of the role of this selection, other than excluding 
significant changes in expression level or protein trafficking efficiency. However, even this 
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conclusion must be taken with some reservation, as it is possible the non-B motif in MERTK’s 
coding region may act in a cis- or trans-fashion to modify MERTK expression or splicing when 
under the control of the endogenous promoter129,130. Our use of a CMV promotor and an intron-
free transgene means that we cannot exclude the possibility that the formation of the non-B 
cruciform motif may regulate expression from the endogenous promotor or regulate other aspects 
of RNA processing. Alternatively, the presence of the non-B DNA and/or the associated amino 
acid substitutions may influence interactions between the RNA or polypeptide with intracellular 
RNA-binding or protein processing machinery – either endogenous – or pathogen-derived. 
Potential effects of these motifs on the promotor could be assessed using a luciferase-based 
promotor activity assay. Assessing the latter possibilities is more difficult, especially if a pathogen-
derived factor drove this evolution, but it may be possible to assess changes in interactions with 
endogenous factors through conventional RNA interaction and protein interaction assays. 
 
4.4 MERTK transmembrane evolution 
In transmembrane evolution, the helical core is in general found to be highly conserved, with 
reduced conservation in the lipid-exposed regions and oligomerizing surfaces108,131. In this study, 
we observed multiple amino acids under positive selection in primates, with a number of these 
changes adding leucines or isoleucines. Research has shown that TAM receptor homodimerize, 
but the specific interactions involved remain unclear. However, MET - a hepatocyte growth factor 
with high transmembrane similarity to TAM receptors8 – has been shown to dimerize through 
similar leucine motifs132. Furthermore, the RTK family member DDR1, which is involved in 
communication with the microenvironment and contains a transmembrane domain similar to that 
of TAM receptors, has been shown to require leucine zippering to dimerize and activate8,133. As 
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additions of leucines and isoleucines can lead to zippering motifs, which are found in other RTKs, 
and areas of oligomerization have less conservation, we evaluated MERTK oligomerization. Our 
study demonstrated increased levels of protein oligomerization in human and hominid MERTK 
compared to primate MERTK. 
 
In our investigations we observed a clear functional impact due to transmembrane evolution. 
Specifically, a dramatic and significant increase in MERTK self-clustering was observed, which 
is likely due to the evolution of a new hydrophobic interaction in the MERTK transmembrane 
domain during the divergence of hominids from primates. Indeed, in silico analysis conducted by 
our collaborators (Appendix 5) demonstrated that many of the leucine/isoleucine additions to 
MERTK occurred along a single facet, consistent with the formation of a leucine-zipper like motif. 
This increase in clustering could indicate one of two evolutionary processes – firstly, increased 
self-clustering is known to increase avidity, and therefore would act to enhance MERTK’s binding 
capacity134. Secondly, the observed increase in clustering may not be due to self-clustering, and 
rather may indicate the presence of new inter-protein interactions. In this case, MERTK may 
engage in new signalling or biological functions through cooperation with new accessory 
molecules. It is important to note that these two possibilities are not mutually exclusive, and that 
this clustering may be indicative of both increased avidity and altered/expanded MERTK activity. 
In future experiments, specific protein interactions can be assessed directly by 
immunoprecipitating MERTK under conditions which preserve its interprotein interactions, 
followed by detection of any interacting proteins by immunoblotting or mass spectrometry113. 
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4.5 MERTK-dependent efferocytosis model development 
To evaluate any functional differences from the evolutionary changes to the transmembrane 
domain, as well as evaluation of the effect of disease-related SNPs on efferocytosis and to fully 
elucidate MERTK’s efferocytosis signalling pathway, it was important to create a reproducible in 
vitro efferocytosis model. While many primary cell types and cell lines endogenously express 
TAM receptors, they tend to express multiple TAM receptors plus additional efferocytic and 
scavenger receptors, making studies of individual receptors in these cell difficult57,73,135. As such, 
we chose to develop an ectopic expression based assay in cells that are not normally efferocytic. 
This would ensure all observations could be ascribed to the activity of the transfected receptors. 
While we were able to develop a functioning system using murine MERTK, our evolutionary 
results revealed that a high degree of divergence occurred in the primate/hominid/human lineage, 
with a concordant alteration of MERTK clustering and possibly MERTK signalling or function, 
thus making any human extrapolations from mouse MerTK models questionable.  
 
Creating a model system to study human MERTK proved to be much more complicated, as human 
MERTK contains multiple motifs recognized by bacteria as recombination and phage sites, making 
cloning of the native sequence impossible. In fact, no studies have yet been published using ectopic 
expression of full-length human MERTK, with a recent study characterizing human MERTK as 
“refractory to cloning”12. Indeed, the only studies using ectopically expressed human MERTK only 
expressed the extracellular or intracellular domains in a soluble form25,85,136. Based on this, it is 
not surprising that most studies on MERTK have used rat or mouse MerTK knockout models, 
which must be interpreted with caution given the scale of recent MERTK evolution in the primate 
lineage. Due to time constraints we were unable to create a functioning efferocytosis model using 
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ectopic human MERTK expression, although, given the lack of efferocytosis observed with our 
positive control (TIM-4), it suggests that there was an issue either with the lipids used to prepare 
our target beads, or with the cell type used for the experiments. However, the same cell line used 
in our efferocytosis experiments are highly phagocytic when expressing the FcγRIIA phagocytic 
receptor (data not shown), and have been extensively used in other phagocytosis assays80,137,138, 
indicating that the issue most likely lies in the lipids used in our model. Future work will use ACs 
or alternative lipid mixtures in place of the PtdChol/PtdSer-coated beads. 
 
While an ectopic expression in vitro model system would be ideal, as it allows us to study MERTK 
in relative isolation from other efferocytic receptors, validation of any results from such a model 
would need to be verified using a more biologically relevant system. To this end, we started 
preliminary work on creating a model system using primary human macrophages. We isolated 
monocytes from human blood and differentiated the macrophages into M0, M1, M2 and M2c 
phenotypes. MERTK is most highly expressed on M0 and M2c phenotypes, which are 
nonpolarized and an anti-inflammatory phenotype respectively. We found that these phenotypes 
were also the most efferocytic cells when fed apoptotic mimics coated in human serum, consistent 
with a study by Zizzo et al. which demonstrated higher levels of efferocytosis when monocytes 
were differentiated with M-CSF (M0) and the highest rate of efferocytosis in M-CSF and IL-10 
differentiated monocytes (M2c)88. Although this assay is not specific for MERTK, it is interesting 
that MERTK high-expressing cells were the most efferocytic. In macrophages AXL is highly 
expressed on inflammatory M1 phenotypes33 which exhibited background levels of efferocytosis 
in our assay. This may highlight MERTK as the essential efferocytic TAM receptor in 
macrophages, and moreover, raises questions about the efferocytic capacity of AXL compared to 
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MERTK. Future work using a macrophage model will require either overexpression of MERTK 
through transfection, or alternatively, pharmacological or siRNA inhibition of MERTK to ensure 
MERTK function is more specifically evaluated.  
 
4.6 MERTK functional domains 
TAM receptors bind to the SHBG domain on opsonins GAS6 and/or PROS through their Ig 
domains25–28. In our study, we found high levels of conservation in Ig1 and neutral selection in Ig2 
of MERTK. In marked contrast, we observed high levels of conservation in Ig2 but neutral selection 
in Ig1 in AXL. TYRO3 showed relative conservation in both Ig domains. These observations may 
explain the differential usage of GAS6, PROS and other TAM opsonins by TAM receptors, with 
binding to certain opsonins lost as the respective Ig domain underwent drift. Unexpectedly, Sasaki 
et al. demonstrated using human AXL Ig domains that Ig1 is more critical for GAS6 binding25. 
However, this study used purified Ig domains rather than intact AXL, and thus binding 
experiments should be conducted using full-length AXL to account for this discrepancy. Apart 
from potential differences in opsonin binding to full length TAM receptors compared to their 
soluble counterparts, there may also be differences in binding patterns when the opsonins are 
bound to PtdSer. Indeed, this is the case with MERTK, which preferentially binds to PtdSer-
engaged GAS632,33. Thus, future studies into TAM-opsonin interactions should use whole TAM 
receptors, and ligand-bound opsonins, to most accurately assess individual Ig domain preferences. 
 
Interestingly, differential opsonin binding sites in the Ig domains of TAM receptors may permit 
heterodimerization. Although homodimerization of TAM receptors has been shown, the ability for 
TAM receptors to heterodimerize remains unexplored, but widely speculated1,57,60,64,139. Other 
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RTKs, like the EGFR family members, have been shown to both homo- and heterodimerize, and 
in doing so increase the diversity of their ligand-binding and signalling capacities140. Potential 
heterodimerization is supported by the fact that while MerTK-/- mice show near abolishment in 
efferocytosis, Axl-/-, Tyro3-/-, and Axl/Tyro3-/- mice show a 50% reduction, demonstrating probable 
interactions among the receptors57. Furthermore, cooperation between AXL and TYRO3 has been 
demonstrated in the Rat2 cell line, where overexpression of TYRO3 – but not a kinase-dead 
TYRO3 – increased GAS6-mediated AXL phosphorylation64. This close interaction is supported 
by the co-immunoprecipitation of TYRO3 and AXL in gonadotropin-releasing hormone neuronal 
cells141. Understanding these interactions will be critical to understanding TAM receptor biology, 
and will likely require crystal structures and in silico analysis with ligand-bound opsonins. Studies 
should use human TAM receptors for all heterodimerization studies, as recent divergence in 
MERTK may impact any inter-protein associations.  
 
While the Fbg domains present on TAM receptor ectodomains are common among RTKs, they 
currently have no defined function142. However, we found that Fbg1 is highly conserved in both 
AXL and MERTK, and Fbg2 is highly conserved in AXL. These domains may have functional 
importance, as purifying selection is typically found in areas critical for protein function143. 
Integrins have been shown to interact with Fbg domains on other proteins through the common-
integrin binding site RGD144, which is not present in MERTK. However, recent findings have 
shown integrin binding to Fbg domains in the absence of RGD145. Thus, conservation in the Fbg 
domains of AXL and MERTK may be due to interactions with integrins, or potentially due to 
interactions with other unelucidated binding partners. This potential binding site should be 
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investigated through co-immunoprecipitation assays using human stimulated TAM receptors with 
or without mutated Fbg domains.  
 
The most critical region in TAM receptors is their TKD, through which all TAM-derived cellular 
signals are believed to be generated1,120,146. Thus, unsurprisingly, we found the TKD to be strongly 
conserved in all three TAM receptors, with stronger conservation observed in AXL and MERTK. 
The higher degree of conservation may be due to the greater importance of MERTK and AXL in 
maintaining homeostasis. Indeed, Axl-/-MerTK-/- mice accumulate the highest number of ACs, as 
well as the worst phenotypes among TAM KO mice147.  
 
4.8 Summary and future aims 
In summary, I have identified two areas of positive selection unique to MERTK among TAM 
receptors. This positive selection is restricted to two key structural domains in MERTK: the signal 
peptide and transmembrane domain. Through reconstruction of the primate and hominid ancestral 
signal peptide and transmembrane domain, I have identified specific nucleotide and residue 
changes in MERTK and have used chimeric MERTK constructs containing the ancestral signal 
peptides or transmembrane domains to evaluate the biological implications of these changes. 
Evolutionary changes in the signal peptide were evaluated for possible changes in protein 
expression and trafficking, with no significant differences observed. We evaluated the ancestral 
transmembrane domains for changes in MERTK self-clustering and found that human and hominid 
MERTK clustered significantly more than primate-ancestral MERTK, despite all three constructs 
displaying roughly equal total and cell surface expression. This increase in clustering appears to 
be due to the evolution of a new hydrophobic interaction motif within the transmembrane domain, 
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although whether this motif mediates homodimerization or the formation of complexes with other 
co-receptors remains to be elucidated. This work indicates that recent evolution has altered 
MERTK function, which could relate to viral pressure or changes in immunological function. 
Progress was made on a mouse MERTK efferocytosis model, but, as evidenced by our 
evolutionary data, human MERTK has undergone significant evolutionary change, necessitating 
the development of a human MERTK model system for future studies. 
 
In future experiments evolutionary analysis should be conducted on non-coding regions of 
MERTK. These regions have been associated with numerous disease-related SNPs, and may unveil 
other key regions that have undergone selection. Furthermore, as positive selection has been shown 
to occur in multiple proteins in the same signalling cascade122, proteins known to be involved in 
MERTK signalling should undergo selection analysis. This may identify which components of the 
MERTK-induced signalling cascade, if any, have undergone positive selection alongside MERTK. 
These analyses may provide further insight into the normal signalling of human MERTK, and 
moreover, may provide insight into the source of the selective pressure which mediated recent 
MERTK evolution. Lastly, the human MERTK in vitro efferocytosis model will enable the study 
of MERTK signalling, as well as functional impacts of recent evolutionary changes or disease-
related SNPs on efferocytosis capacity. These analyses will provide insight into MERTK’s cellular 
function, identifying critical signalling components and functional domains, thereby identifying 
potential therapeutic targets. 
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Appendix 
 
               10        20        30        40        50        60        70        80        90       100 
MerTK  ATGGGGCCGGCCCCGCTGCCGCTGCTGCTGGGCCTCTTCCTCCCCGCGCTCTGGCGTAGAGCTATCACTGAGGCAAGGGAAGAAGCCAAGCCTTACCCGC 
Opt.   .....A..C..A..A.....A...........A..G..T..G..T..T..G...A.AC.G.....T..C..A..T.....G..G..T.....A.....C. 
 
              110       120       130       140       150       160       170       180       190       200 
MerTK  TATTCCCGGGACCTTTTCCAGGGAGCCTGCAAACTGACCACACACCGCTGTTATCCCTTCCTCACGCCAGTGGGTACCAGCCTGCCTTGATGTTTTCACC 
Opt.   .G..T..T..G..A..C..C..A........G..C...........A...C.G..A..G..C..T.....C..C..T.....C..AC.......C..C.. 
 
              210       220       230       240       250       260       270       280       290       300 
MerTK  AACCCAGCCTGGAAGACCACATACAGGAAACGTAGCCATTCCCCAGGTGACCTCTGTCGAATCAAAGCCCCTACCGCCTCTTGCCTTCAAACACACAGTT 
Opt.   T..T.....A..CC.G..C..C..C........G.....C..T..A.....T..C........T.....A..G..C.....G.....T........C..G 
 
              310       320       330       340       350       360       370       380       390       400 
MerTK  GGACACATAATACTTTCTGAACATAAAGGTGTCAAATTTAATTGCTCAATCAGTGTACCTAATATATACCAGGACACCACAATTTCTTGGTGGAAAGATG 
Opt.   ..G..T..C..T..G..C..G.....G..A........C........C...TC...G..C..C..C.............................G.... 
 
              410       420       430       440       450       460       470       480       490       500 
MerTK  GGAAGGAATTGCTTGGGGCACATCATGCAATTACACAGTTTTATCCAGATGATGAAGTTACAGCAATAATCGCTTCCTTCAGCATAACCAGTGTGCAGCG 
Opt.   .A..A..GC....G..C..C..C.....T..C..T...........T..C........C..C.....C..T..CAGT...TCA..C..ATCA......A. 
 
              510       520       530       540       550       560       570       580       590       600 
MerTK  TTCAGACAATGGGTCGTATATCTGTAAGATGAAAATAAACAATGAAGAGATCGTGTCTGATCCCATCTACATCGAAGTACAAGGACTTCCTCACTTTACT 
Opt.   AAGC..T........C..C.....C...........T........G..A.....CAGC..C..T.....T..T..G..G..G.....G...........A 
 
              610       620       630       640       650       660       670       680       690       700 
MerTK  AAGCAGCCTGAGAGCATGAATGTCACCAGAAACACAGCCTTCAACCTCACCTGTCAGGCTGTGGGCCCGCCTGAGCCCGTCAACATTTTCTGGGTTCAAA 
Opt.   ........A..ATC......C..G..T..G..T..C..T........G..T........A.....A..A..C.....T..G.....C..T.....C..G. 
 
              710       720       730       740       750       760       770       780       790       800 
MerTK  ACAGTAGCCGTGTTAACGAACAGCCTGAAAAATCCCCCTCCGTGCTAACTGTTCCAGGCCTGACGGAGATGGCGGTCTTCAGTTGTGAGGCCCACAATGA 
Opt.   .T..CTC...C..G.....G...........GAG...A........G..C..C...........A........C..G.....C.....A..T........ 
 
              810       820       830       840       850       860       870       880       890       900 
MerTK  CAAAGGGCTGACCGTGTCCAAGGGAGTGCAGATCAACATCAAAGCAATTCCCTCCCCACCAACTGAAGTCAGCATCCGTAACAGCACTGCACACAGCATT 
Opt.   ...G..C..............A..G..C..............G..C.....T..T..T........G..GTCT...A.G..T..T..C..T..TTCA..C 
 
              910       920       930       940       950       960       970       980       990      1000 
MerTK  CTGATCTCCTGGGTTCCTGGTTTTGATGGATACTCCCCGTTCAGGAATTGCAGCATTCAGGTCAAGGAAGCTGATCCGCTGAGTAATGGCTCAGTCATGA 
Opt.   .....TAG......G..C..C........G...AG...T...C.C..C...TC...C...........G..C..C..T.................G.... 
 
             1010      1020      1030      1040      1050      1060      1070      1080      1090      1100 
MerTK  TTTTTAACACCTCTGCCTTACCACATCTGTACCAAATCAAGCAGCTGCAAGCCCTGGCTAATTACAGCATTGGTGTTTCCTGCATGAATGAAATAGGCTG 
Opt.   .C..C......AGC...C.G.....C........G.....A........G..T.....A.....TTC......A..C..T..T.....C..G..C..A.. 
 
             1110      1120      1130      1140      1150      1160      1170      1180      1190      1200 
MerTK  GTCTGCAGTGAGCCCTTGGATTCTAGCCAGCACGACTGAAGGAGCCCCATCAGTAGCACCTTTAAATGTCACTGTGTTTCTGAATGAATCTAGTGATAAT 
Opt.   .AGC..C...TC...C........G..TTCT..T..C.....C..T..CAGT..G......C.G.....G..C..C..C........G........C..C 
 
             1210      1220      1230      1240      1250      1260      1270      1280      1290      1300 
MerTK  GTGGACATCAGATGGATGAAGCCTCCGACTAAGCAGCAGGATGGAGAACTGGTGGGCTACCGGATATCCCACGTGTGGCAGAGTGCAGGGATTTCCAAAG 
Opt.   .........C.G...........C..T..A..A...........C........C..G...A.A..T....................C..C..C..A..G. 
 
             1310      1320      1330      1340      1350      1360      1370      1380      1390      1400 
MerTK  AGCTCTTGGAGGAAGTTGGCCAGAATGGCAGCCGAGCTCGGATCTCTGTTCAAGTCCACAATGCTACGTGCACAGTGAGGATTGCAGCCGTCACCAGAGG 
Opt.   ....GC..........G..A.........TC.A.G..A..C..T.....G..G.....T..C..C..A.....T...C.A..C.....T......C.G.. 
 
             1410      1420      1430      1440      1450      1460      1470      1480      1490      1500 
MerTK  GGGAGTTGGGCCCTTCAGTGATCCAGTGAAAATATTTATCCCTGCACACGGTTGGGTAGATTATGCCCCCTCTTCAACTCCGGCGCCTGGCAACGCAGAT 
Opt.   C.....G..A........C..C..C..C..G..T..C.....C........A.....G...........T..AAGC..A..T..A..A..A.....T..C 
 
             1510      1520      1530      1540      1550      1560      1570      1580      1590      1600 
MerTK  CCTGTGCTCATCATCTTTGGCTGCTTTTGTGGATTTATTTTGATTGGGTTGATTTTATACATCTCCTTGGCCATCAGAAAAAGAGTCCAGGAGACAAAGT 
Opt.   ..C.....G.....T..C..A...........C..C..CC.......CC....CC.G.....T...C........C....GC.G..G...........A. 
 
             1610      1620      1630      1640      1650      1660      1670      1680      1690      1700 
MerTK  TTGGGAATGCATTCACAGAGGAGGATTCTGAATTAGTGGTGAATTATATAGCAAAGAAATCCTTCTGTCGGCGAGCCATTGAACTTACCTTACATAGCTT 
Opt.   ..........T.....T.....A..CAG....C.G.....C..C.....T..C........A..T......A....T..C.....G...C.G......C. 
 
             1710      1720      1730      1740      1750      1760      1770      1780      1790      1800 
MerTK  GGGAGTCAGTGAGGAACTACAAAATAAACTAGAAGATGTTGTGATTGACAGGAATCTTCTAATTCTTGGAAAAATTCTGGGTGAAGGAGAGTTTGGGTCT 
Opt.   ...C..GTCC........G..G.....G..G..G..C..G..C..C..T.....C..G..G..C..G..............G..G........C...... 
 
             1810      1820      1830      1840      1850      1860      1870      1880      1890      1900 
MerTK  GTAATGGAAGGAAATCTTAAGCAGGAAGATGGGACCTCTCTGAAAGTGGCAGTGAAGACCATGAAGTTGGACAACTCTTCACAGCGGGAGATCGAGGAGT 
Opt.   ..G.....G........G..............C..AAG............C..C.....T.....AC..........C..T.................A. 
 
             1910      1920      1930      1940      1950      1960      1970      1980      1990      2000 
MerTK  TTCTCAGTGAGGCAGCGTGCATGAAAGACTTCAGCCACCCAAATGTCATTCGACTTCTAGGTGTGTGTATAGAAATGAGCTCTCAAGGCATCCCAAAGCC 
Opt.   ....GTCA..A.....C........G..T..............C......A....G..G..C.....C..C..G.....T..A..G..G..T..C..... 
 
             2010      2020      2030      2040      2050      2060      2070      2080      2090      2100 
MerTK  CATGGTAATTTTACCCTTCATGAAATACGGGGACCTGCATACTTACTTACTTTATTCCCGATTGGAGACAGGACCAAAGCATATTCCTCTGCAGACACTA 
Opt.   T.....C..CC.G.....T....................C......C.G..G.....T..CC.......C.....T...........A........C..G 
 
             2110      2120      2130      2140      2150      2160      2170      2180      2190      2200 
MerTK  TTGAAGTTCATGGTGGATATTGCCCTGGGAATGGAGTATCTGAGCAACAGGAATTTTCTTCATCGAGATTTAGCTGCTCGAAACTGCATGTTGCGAGATG 
Opt.   C................C..C........G........C...TC....C.......C..G...A....CC.G.....AA.G..T......C....C..C. 
 
             2210      2220      2230      2240      2250      2260      2270      2280      2290      2300 
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MerTK  ACATGACTGTCTGTGTTGCGGACTTCGGCCTCTCTAAGAAGATTTACAGTGGCGATTATTACCGCCAAGGCCGCATTGCTAAGATGCCTGTTAAATGGAT 
Opt.   .T.....C..G..C..G..C.....T..A..GAGC.....A..C...TCA..A.....C..TA.A..G...A.G..C..C........C..C........ 
 
             2310      2320      2330      2340      2350      2360      2370      2380      2390      2400 
MerTK  CGCCATAGAAAGTCTTGCAGACCGAGTCTACACAAGTAAAAGTGATGTGTGGGCATTTGGCGTGACCATGTGGGAAATAGCTACGCGGGGAATGACTCCC 
Opt.   ...A..T.....C..G..C........G......TC...G........C.....T..C........T........G..T..A..AA.A..G........A 
 
             2410      2420      2430      2440      2450      2460      2470      2480      2490      2500 
MerTK  TATCCTGGGGTCCAGAACCATGAGATGTATGACTATCTTCTCCATGGCCACAGGTTGAAGCAGCCCGAAGACTGCCTGGATGAACTGTATGAAATAATGT 
Opt.   .....C..A..G........C........C..T.....G..G..C..G..TC..C..........A.................G.....C.....C.... 
 
             2510      2520      2530      2540      2550      2560      2570      2580      2590      2600 
MerTK  ACTCTTGCTGGAGAACCGATCCCTTAGACCGCCCCACCTTTTCAGTATTGAGGCTGCAGCTAGAAAAACTCTTAGAAAGTTTGCCTGACGTTCGGAACCA 
Opt.   .TAGC..T...........C...C.G..TA.G..T..A..CAGT..GC..C.C........G..G.....GC.G...TCAC....C.....G..A..T.. 
 
             2610      2620      2630      2640      2650      2660      2670      2680      2690      2700 
MerTK  AGCAGACGTTATTTACGTCAATACACAGTTGCTGGAGAGCTCTGAGGGCCTGGCCCAGGGCTCCACCCTTGCTCCACTGGACTTGAACATCGACCCTGAC 
Opt.   G..C..T..G..C........C..C...C...........AGC..A..G.....A......AG......G..C.........C....T..T.....C..T 
 
             2710      2720      2730      2740      2750      2760      2770      2780      2790      2800 
MerTK  TCTATAATTGCCTCCTGCACTCCCCGCGCTGCCATCAGTGTGGTCACAGCAGAAGTTCATGACAGCAAACCTCATGAAGGACGGTACATCCTGAATGGGG 
Opt.   .....C.....AAGT.........A.G..C..T...TCC........C..T..G..G..C..TTCT..G...........C..C..T........C..A. 
 
             2810      2820      2830      2840      2850      2860      2870      2880      2890      2900 
MerTK  GCAGTGAGGAATGGGAAGATCTGACTTCTGCCCCCTCTGCTGCAGTCACAGCTGAAAAGAACAGTGTTTTACCGGGGGAGAGACTTGTTAGGAATGGGGT 
Opt.   ..TC............G..C.....C.....T..AAG...A..C........A..G..A..T..C..GC.G..A..A..AC.C..G..GC.A..C..... 
 
             2910      2920      2930      2940         2950      2960      2970      2980      2990        
MerTK  CTCCTGGTCCCATTCGAGCATGCTGCCCTTGGGAAGCTCAT---TGCCCGATGAACTTTTGTTTGCTGACGACTCCTCAGAAGGCTCAGAAGTCCTGATG 
Opt.   ...A...AG...C..T..T.........C...---.....AGCC....A..C.....GC..........T..T..AAGC..G..G..C..G..G...... 
 
      3000 
MerTK  TGA 
Opt.   .A. 
 
 
Appendix 1:  Codon-optimized MERTK sequence. Alignment of the codon-optimized MERTK 
construct (Opt.) with the human MERTK mRNA coding region (MERTK). The amino acid 
sequence of the Opt construct is identical to the sequence encoded by the MERTK mRNA.  
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Appendix 2:  Ethics approval for performing venipuncture on human participants.  
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Appendix 3:  Fisher’s Exact Test of Neutrality for Sequence Pairs for TAM receptors. All 
available primate sequences for TYRO3 (A), AXL (B), and MERTK (C) were used to test the 
probability of rejecting the null hypothesis of strict neutrality in favour of a hypothesis of positive 
selection for each sequence pair. Data are represented as p-values, where p values less than 0.05 
are significant.  
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
 
A) 
 
B) 
 
C) 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
Homo sapiens 1
Pan troglodytes 2 0.672
Papio anubis 3 1.000 1.000
Pan paniscus 4 0.671 1.000 1.000
Callithrix jacchus 5 1.000 1.000 1.000 1.000
Chlorocebus sabaeus 6 1.000 1.000 1.000 1.000 1.000
Gorilla gorilla 7 1.000 1.000 1.000 1.000 1.000 1.000
Saimiri boliviensis 8 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Pongo abelii 9 0.465 0.583 1.000 0.413 0.339 1.000 0.364 0.339
Nomascus leucogenys 10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0.267
Macaca mulatta 11 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Macaca fascicularis 12 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Tarsius syrichta 13 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0.321 1.000 1.000 1.000
Otolemur garnettii 14 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Homo sapiens 1
Gorilla gorilla 2 1.000
Callithrix jacchus 3 1.000 1.000
Pan paniscus 4 0.567 1.000 1.000
Tarsius syrichta 5 1.000 1.000 1.000 1.000
Chlorocebus sabaeus 6 0.453 1.000 1.000 0.565 1.000
Otolemur garnettii 7 1.000 1.000 1.000 1.000 1.000 1.000
Pongo abelii 8 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Papio anubis 9 1.000 1.000 1.000 1.000 1.000 0.620 1.000 1.000
Saimiri boliviensis 10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Pan troglodytes 11 1.000 1.000 1.000 1.000 1.000 0.480 1.000 1.000 1.000 1.000
Nomascus leucogenys 12 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Macaca fascicularis 13 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Homo sapiens 1
Gorilla gorilla 2 1.000
Pongo abelii 3 1.000 1.000
Pan troglodytes 4 1.000 1.000 1.000
Nomascus leucogenys 5 1.000 1.000 1.000 1.000
Macaca mulatta 6 1.000 1.000 1.000 1.000 1.000
Macaca fascicularis 7 1.000 1.000 1.000 1.000 1.000 1.000
Papio anubis 8 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Tarsius syrichta 9 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Chlorocebus sabaeus 10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Saimiri boliviensis 11 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Otolemur garnettii 12 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
MERTK
AXL
TYRO3
1 2 3 4 5 6 7 8 9 10 11 12
Homo sapiens 1
Pan troglodytes 2 0.672
Papio anubis 3 1.000 1.000
Pan paniscus 4 0.671 1.000 1.000
Callithrix jacchus 5 1.000 1.000 1.000 1.000
Chlorocebus sabaeus 6 1.000 1.000 1.000 1.000 1.000
Gorilla gorilla 7 1.000 1.000 1.000 1.000 1.000 1.000
Saimiri boliviensis 8 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Pongo abelii 9 0.465 0.583 1.000 0.413 0.339 1.000 0.364 0.339
Nomascus leucogenys 10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0.267
Macaca mulatta 11 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Macaca fascicularis 12 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Tarsius syrichta 13 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0.321 1.000 1.000 1.000
Otolemur garnettii 14 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Homo sapiens 1
Gorilla gorilla 2 1.000
Callithrix jacchus 3 1.000 1.000
Pan paniscus 4 0.567 1.000 1.000
Tarsius syrichta 5 1.000 1.000 1.000 1.000
Chlorocebus sabaeus 6 0.453 1.000 1.000 0.565 1.000
Otolemur garnettii 7 1.000 1.000 1.000 1.000 1.000 1.000
Pongo abelii 8 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Papio anubis 9 1.000 1.000 1.000 1.000 1.000 0.620 1.000 1.000
Saimiri boliviensis 10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Pan troglodytes 11 1.000 1.000 1.000 1.000 1.000 0.480 1.000 1.000 1.000 1.000
Nomascus leucogenys 12 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Macaca fascicularis 13 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Homo sapiens 1
Gorilla gorilla 2 1.000
Pongo abelii 3 1.000 1.000
Pan troglodytes 4 1.000 1.000 1.000
Nomascus leucogenys 5 1.000 1.000 1.000 1.000
Macaca mulatta 6 1.000 1.000 1.000 1.000 1.000
Macaca fascicularis 7 1.000 1.000 1.000 1.000 1.000 1.000
Papio anubis 8 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Tarsius syrichta 9 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Chlorocebus sabaeus 10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Saimiri boliviensis 11 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Otolemur garnettii 12 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
MERTK
AXL
TYRO3
1 2 3 4 5 6 7 8 9 10 11 12
Homo sapiens 1
Pan troglodytes 2 0.672
Papio anubis 3 1.000 1.000
Pan paniscus 4 0.671 1.000 1.000
Callithrix jacchus 5 1.000 1.000 1.000 1.000
Chlorocebus sabaeus 6 1.000 1.000 1.000 1.000 1.000
Gorilla gorilla 7 1.000 1.000 1.000 1.000 1.000 1.000
Saimiri boliviensis 8 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Pongo abelii 9 0.465 0.583 1.000 0.413 0.339 1.000 0.364 0.339
Nomascus leucogenys 10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0.267
Macaca mulatta 11 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Macaca fascicularis 12 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Tarsius syrichta 13 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0.321 1.000 1.000 1.000
Otolemur garnettii 14 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Homo sapiens 1
Gorilla gorilla 2 1.000
Callithrix jacchus 3 1.000 1.000
Pan paniscus 4 0.567 1.000 1.000
Tarsius syrichta 5 1.000 1.000 1.000 1.000
Chlorocebus sabaeus 6 0.453 1.000 1.000 0.565 1.000
Otolemur garnettii 7 1.000 1.000 1.000 1.000 1.000 1.000
Pongo abelii 8 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Papio anubis 9 1.000 1.000 1.000 1.000 1.000 0.620 1.000 1.000
Saimiri boliviensis 10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Pan troglodytes 11 1.000 1.000 1.000 1.000 1.000 0.480 1.000 1.000 1.000 1.000
Nomascus leucogenys 12 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Macaca fascicularis 13 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Homo sapiens 1
Gorilla gorilla 2 1.000
Pongo abelii 3 1.000 1.000
Pan troglodytes 4 1.000 1.000 1.000
Nomascus leucogenys 5 1.000 1.000 1.000 1.000
Macaca mulatta 6 1.000 1.000 1.000 1.000 1.000
Macaca fascicularis 7 1.000 1.000 1.000 1.000 1.000 1.000
Papio anubis 8 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Tarsius syrichta 9 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Chlorocebus sabaeus 10 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Saimiri boliviensis 11 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Otolemur garnettii 12 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
MERTK
AXL
TYRO3
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Appendix 4:  Z-Tests for TAM receptors. Whole gene evolutionary Z-tests were conducted 
using the Nei-Gojobori method in MEGA6 using all available primate sequences from TYRO3 
(A), AXL (B), and MERTK (C). Tests show the probability of rejecting the null hypothesis of 
strict-neutrality,   purifying or positive selection for each TAM receptor. Values of p are shown 
in the bottom left of each table and values less than 0.05 are considered significant.   Test values 
are shown in the right diagonal section of each table; Ka – Ks for neutral and positive selection, 
and Ks – Ka for purifying selection. 
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A) 
 
 
 
 
 
 
  
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Homo sapiens 1 0.0177 -1.3565 0.0179 -0.7406 -1.3592 -0.8380 -1.0027 0.4108 -0.7366 -1.6423 -1.6255 -2.9270 -4.0163
Pan troglodytes 2 0.9859 -1.2718 -0.8883 -0.5071 -1.2746 -1.0679 -1.1326 0.1130 -0.9322 -1.5588 -1.5388 -2.8352 -4.1119
Papio anubis 3 0.1775 0.2059 -0.7366 -0.6756 -0.9748 -1.1810 -0.5957 -0.8844 -1.5217 -0.3126 -0.1854 -2.3948 -4.0503
Pan paniscus 4 0.9858 0.3761 0.4628 -0.5064 -0.7395 -0.4685 -0.7884 0.5987 -0.4015 -1.0515 -1.0145 -2.8352 -3.9476
Callithrix jacchus 5 0.4604 0.6130 0.5006 0.6135 -1.0553 -0.5963 -1.5207 0.7954 -0.8615 -0.7506 -0.8653 -3.5887 -3.9973
Chlorocebus sabaeus 6 0.1766 0.2049 0.3316 0.4610 0.2934 -1.1844 -0.8084 -0.3772 -1.6735 -1.2633 -1.3934 -2.3948 -3.9825
Gorilla gorilla 7 0.4037 0.2877 0.2399 0.6402 0.5521 0.2386 -0.8107 1.0013 -1.1025 -1.4386 -1.4123 -3.1806 -4.0325
Saimiri boliviensis 8 0.3180 0.2596 0.5525 0.4320 0.1310 0.4205 0.4191 0.8062 -1.2234 -0.9406 -0.9072 -3.4236 -3.9609
Pongo abelii 9 0.6820 0.9102 0.3783 0.5505 0.4280 0.7067 0.3187 0.4217 1.0401 -0.7537 -0.6109 2.1350 -0.0950
Nomascus leucogenys 10 0.4628 0.3531 0.1307 0.6888 0.3907 0.0968 0.2724 0.2236 0.3004 -1.3362 -1.7470 -2.1560 -3.4313
Macaca mulatta 11 0.1031 0.1217 0.7551 0.2951 0.4543 0.2089 0.1529 0.3488 0.4525 0.1840 -1.0825 -2.2071 -4.2012
Macaca fascicularis 12 0.1067 0.1265 0.8533 0.3124 0.3886 0.1661 0.1604 0.3661 0.5424 0.0832 0.2812 -2.5764 -4.1151
Tarsius syrichta 13 0.0041 0.0054 0.0182 0.0054 0.0005 0.0182 0.0019 0.0008 0.0348 0.0331 0.0292 0.0112 -3.6473
Otolemur garnettii 14 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.9245 0.0008 0.0001 0.0001 0.0004
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Homo sapiens 1 -0.0177 1.3565 -0.0179 0.7406 1.3592 0.8380 1.0027 -0.4108 0.7366 1.6423 1.6255 2.9270 4.0163
Pan troglodytes 2 1.0000 1.2718 0.8883 0.5071 1.2746 1.0679 1.1326 -0.1130 0.9322 1.5588 1.5388 2.8352 4.1119
Papio anubis 3 0.0887 0.1029 0.7366 0.6756 0.9748 1.1810 0.5957 0.8844 1.5217 0.3126 0.1854 2.3948 4.0503
Pan paniscus 4 1.0000 0.1881 0.2314 0.5064 0.7395 0.4685 0.7884 -0.5987 0.4015 1.0515 1.0145 2.8352 3.9476
Callithrix jacchus 5 0.2302 0.3065 0.2503 0.3067 1.0553 0.5963 1.5207 -0.7954 0.8615 0.7506 0.8653 3.5887 3.9973
Chlorocebus sabaeus 6 0.0883 0.1025 0.1658 0.2305 0.1467 1.1844 0.8084 0.3772 1.6735 1.2633 1.3934 2.3948 3.9825
Gorilla gorilla 7 0.2018 0.1439 0.1200 0.3201 0.2761 0.1193 0.8107 -1.0013 1.1025 1.4386 1.4123 3.1806 4.0325
Saimiri boliviensis 8 0.1590 0.1298 0.2763 0.2160 0.0655 0.2102 0.2096 -0.8062 1.2234 0.9406 0.9072 3.4236 3.9609
Pongo abelii 9 1.0000 1.0000 0.1891 1.0000 1.0000 0.3534 1.0000 1.0000 -1.0401 0.7537 0.6109 -2.1350 0.0950
Nomascus leucogenys 10 0.2314 0.1765 0.0654 0.3444 0.1953 0.0484 0.1362 0.1118 1.0000 1.3362 1.7470 2.1560 3.4313
Macaca mulatta 11 0.0516 0.0608 0.3776 0.1476 0.2272 0.1045 0.0764 0.1744 0.2262 0.0920 1.0825 2.2071 4.2012
Macaca fascicularis 12 0.0533 0.0632 0.4266 0.1562 0.1943 0.0830 0.0802 0.1831 0.2712 0.0416 0.1406 2.5764 4.1151
Tarsius syrichta 13 0.0020 0.0027 0.0091 0.0027 0.0002 0.0091 0.0009 0.0004 1.0000 0.0165 0.0146 0.0056 3.6473
Otolemur garnettii 14 0.0001 0.0000 0.0000 0.0001 0.0001 0.0001 0.0000 0.0001 0.4622 0.0004 0.0000 0.0000 0.0002
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Homo sapiens 1 0.0177 -1.3565 0.0179 -0.7406 -1.3592 -0.8380 -1.0027 0.4108 -0.7366 -1.6423 -1.6255 -2.9270 -4.0163
Pan troglodytes 2 0.4930 -1.2718 -0.8883 -0.5071 -1.2746 -1.0679 -1.1326 0.1130 -0.9322 -1.5588 -1.5388 -2.8352 -4.1119
Papio anubis 3 1.0000 1.0000 -0.7366 -0.6756 -0.9748 -1.1810 -0.5957 -0.8844 -1.5217 -0.3126 -0.1854 -2.3948 -4.0503
Pan paniscus 4 0.4929 1.0000 1.0000 -0.5064 -0.7395 -0.4685 -0.7884 0.5987 -0.4015 -1.0515 -1.0145 -2.8352 -3.9476
Callithrix jacchus 5 1.0000 1.0000 1.0000 1.0000 -1.0553 -0.5963 -1.5207 0.7954 -0.8615 -0.7506 -0.8653 -3.5887 -3.9973
Chlorocebus sabaeus 6 1.0000 1.0000 1.0000 1.0000 1.0000 -1.1844 -0.8084 -0.3772 -1.6735 -1.2633 -1.3934 -2.3948 -3.9825
Gorilla gorilla 7 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -0.8107 1.0013 -1.1025 -1.4386 -1.4123 -3.1806 -4.0325
Saimiri boliviensis 8 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 0.8062 -1.2234 -0.9406 -0.9072 -3.4236 -3.9609
Pongo abelii 9 0.3410 0.4551 1.0000 0.2752 0.2140 1.0000 0.1594 0.2109 1.0401 -0.7537 -0.6109 2.1350 -0.0950
Nomascus leucogenys 10 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 0.1502 -1.3362 -1.7470 -2.1560 -3.4313
Macaca mulatta 11 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -1.0825 -2.2071 -4.2012
Macaca fascicularis 12 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -2.5764 -4.1151
Tarsius syrichta 13 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 0.0174 1.0000 1.0000 1.0000 -3.6473
Otolemur garnettii 14 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
Neutrality
Purifying
Positive
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B) 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13
Homo sapiens 1 -0.5088 -1.3002 0.2058 -0.3979 0.4604 -2.6713 -0.2105 -0.1618 -0.4004 -0.2553 -1.3457 -0.6455
Gorilla gorilla 2 0.6118 -1.2288 -0.3377 -0.8055 -0.2089 -2.9325 -0.4659 -0.8667 -0.4538 -0.6060 -2.0506 -1.3273
Callithrix jacchus 3 0.1960 0.2215 -1.7917 -1.1276 -1.0535 -2.2854 -2.3187 -1.3474 -1.6635 -1.6784 -1.5932 -1.8724
Pan paniscus 4 0.8373 0.7362 0.0757 -0.6757 0.1449 -2.8721 -0.4735 -0.4339 -0.9241 -0.2841 -0.6666 -0.6146
Tarsius syrichta 5 0.6914 0.4221 0.2617 0.5006 -0.5798 -2.4211 -1.7638 -1.1104 -0.7436 -0.7059 -0.6508 -1.9622
Chlorocebus sabaeus 6 0.6460 0.8349 0.2942 0.8850 0.5631 -2.5182 -0.4053 0.0239 -0.4158 0.3779 -0.2788 -1.4093
Otolemur garnettii 7 0.0086 0.0040 0.0240 0.0048 0.0170 0.0131 -2.9827 -2.8906 -1.9953 -2.8406 -3.0002 -3.6608
Pongo abelii 8 0.8336 0.6421 0.0221 0.6367 0.0803 0.6860 0.0035 -0.7987 -1.6918 -0.4740 -1.4580 -0.7696
Papio anubis 9 0.8718 0.3879 0.1804 0.6651 0.2690 0.9810 0.0046 0.4261 -0.5296 -0.2232 -0.8064 -1.2528
Saimiri boliviensis 10 0.6896 0.6508 0.0988 0.3573 0.4586 0.6783 0.0483 0.0933 0.5974 -1.0122 -1.4288 -1.9635
Pan troglodytes 11 0.7989 0.5456 0.0959 0.7768 0.4816 0.7061 0.0053 0.6364 0.8237 0.3135 -0.9043 -0.3740
Nomascus leucogenys 12 0.1809 0.0425 0.1138 0.5063 0.5164 0.7808 0.0033 0.1474 0.4216 0.1557 0.3676 -1.5037
Macaca fascicularis 13 0.5199 0.1869 0.0636 0.5400 0.0521 0.1613 0.0004 0.4431 0.2127 0.0519 0.7091 0.1353
1 2 3 4 5 6 7 8 9 10 11 12 13
Homo sapiens 1 0.5088 1.3002 -0.2058 0.3979 -0.4604 2.6713 0.2105 0.1618 0.4004 0.2553 1.3457 0.6455
Gorilla gorilla 2 0.3059 1.2288 0.3377 0.8055 0.2089 2.9325 0.4659 0.8667 0.4538 0.6060 2.0506 1.3273
Callithrix jacchus 3 0.0980 0.1108 1.7917 1.1276 1.0535 2.2854 2.3187 1.3474 1.6635 1.6784 1.5932 1.8724
Pan paniscus 4 1.0000 0.3681 0.0378 0.6757 -0.1449 2.8721 0.4735 0.4339 0.9241 0.2841 0.6666 0.6146
Tarsius syrichta 5 0.3457 0.2111 0.1309 0.2503 0.5798 2.4211 1.7638 1.1104 0.7436 0.7059 0.6508 1.9622
Chlorocebus sabaeus 6 1.0000 0.4174 0.1471 1.0000 0.2816 2.5182 0.4053 -0.0239 0.4158 -0.3779 0.2788 1.4093
Otolemur garnettii 7 0.0043 0.0020 0.0120 0.0024 0.0085 0.0066 2.9827 2.8906 1.9953 2.8406 3.0002 3.6608
Pongo abelii 8 0.4168 0.3211 0.0111 0.3184 0.0402 0.3430 0.0017 0.7987 1.6918 0.4740 1.4580 0.7696
Papio anubis 9 0.4359 0.1939 0.0902 0.3326 0.1345 1.0000 0.0023 0.2130 0.5296 0.2232 0.8064 1.2528
Saimiri boliviensis 10 0.3448 0.3254 0.0494 0.1786 0.2293 0.3391 0.0241 0.0466 0.2987 1.0122 1.4288 1.9635
Pan troglodytes 11 0.3995 0.2728 0.0479 0.3884 0.2408 1.0000 0.0026 0.3182 0.4119 0.1567 0.9043 0.3740
Nomascus leucogenys 12 0.0905 0.0212 0.0569 0.2532 0.2582 0.3904 0.0016 0.0737 0.2108 0.0778 0.1838 1.5037
Macaca fascicularis 13 0.2599 0.0935 0.0318 0.2700 0.0260 0.0807 0.0002 0.2215 0.1064 0.0259 0.3545 0.0676
1 2 3 4 5 6 7 8 9 10 11 12 13
Homo sapiens 1 -0.5088 -1.3002 0.2058 -0.3979 0.4604 -2.6713 -0.2105 -0.1618 -0.4004 -0.2553 -1.3457 -0.6455
Gorilla gorilla 2 1.0000 -1.2288 -0.3377 -0.8055 -0.2089 -2.9325 -0.4659 -0.8667 -0.4538 -0.6060 -2.0506 -1.3273
Callithrix jacchus 3 1.0000 1.0000 -1.7917 -1.1276 -1.0535 -2.2854 -2.3187 -1.3474 -1.6635 -1.6784 -1.5932 -1.8724
Pan paniscus 4 0.4187 1.0000 1.0000 -0.6757 0.1449 -2.8721 -0.4735 -0.4339 -0.9241 -0.2841 -0.6666 -0.6146
Tarsius syrichta 5 1.0000 1.0000 1.0000 1.0000 -0.5798 -2.4211 -1.7638 -1.1104 -0.7436 -0.7059 -0.6508 -1.9622
Chlorocebus sabaeus 6 0.3230 1.0000 1.0000 0.4425 1.0000 -2.5182 -0.4053 0.0239 -0.4158 0.3779 -0.2788 -1.4093
Otolemur garnettii 7 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -2.9827 -2.8906 -1.9953 -2.8406 -3.0002 -3.6608
Pongo abelii 8 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -0.7987 -1.6918 -0.4740 -1.4580 -0.7696
Papio anubis 9 1.0000 1.0000 1.0000 1.0000 1.0000 0.4905 1.0000 1.0000 -0.5296 -0.2232 -0.8064 -1.2528
Saimiri boliviensis 10 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -1.0122 -1.4288 -1.9635
Pan troglodytes 11 1.0000 1.0000 1.0000 1.0000 1.0000 0.3531 1.0000 1.0000 1.0000 1.0000 -0.9043 -0.3740
Nomascus leucogenys 12 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -1.5037
Macaca fascicularis 13 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
Neutrality
Purifying
Positive
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C) 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
Homo sapiens 1 -1.3274 -4.2472 -1.8871 -3.2994 -5.5268 -5.8634 -6.2358 -11.4481 -5.8279 -7.2380 -11.1601
Gorilla gorilla 2 0.1869 -4.2148 -1.8369 -3.5671 -5.4446 -5.7682 -6.2115 -10.7631 -5.9708 -7.3304 -10.7901
Pongo abelii 3 0.0000 0.0000 -4.8435 -3.7643 -5.8965 -6.0396 -6.5839 -11.2897 -5.9812 -7.5660 -11.1269
Pan troglodytes 4 0.0616 0.0687 0.0000 -4.1074 -6.1913 -6.5073 -6.8595 -11.7498 -6.3998 -7.7204 -11.2448
Nomascus leucogenys 5 0.0013 0.0005 0.0003 0.0001 -5.0211 -5.2298 -5.7693 -10.8395 -5.2982 -7.1070 -10.8292
Macaca mulatta 6 0.0000 0.0000 0.0000 0.0000 0.0000 -1.1536 -3.6155 -11.1767 -3.6094 -6.9410 -11.0363
Macaca fascicularis 7 0.0000 0.0000 0.0000 0.0000 0.0000 0.2510 -3.8413 -11.4172 -3.8620 -7.2260 -11.1459
Papio anubis 8 0.0000 0.0000 0.0000 0.0000 0.0000 0.0004 0.0002 -11.6141 -3.8907 -7.3265 -11.4114
Tarsius syrichta 9 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 -11.0365 -10.9746 -11.9989
Chlorocebus sabaeus 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0004 0.0002 0.0002 0.0000 -6.9330 -11.0954
Saimiri boliviensis 11 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 -10.9440
Otolemur garnettii 12 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
1 2 3 4 5 6 7 8 9 10 11 12
Homo sapiens 1 1.3274 4.2472 1.8871 3.2994 5.5268 5.8634 6.2358 11.4481 5.8279 7.2380 11.1601
Gorilla gorilla 2 0.0935 4.2148 1.8369 3.5671 5.4446 5.7682 6.2115 10.7631 5.9708 7.3304 10.7901
Pongo abelii 3 0.0000 0.0000 4.8435 3.7643 5.8965 6.0396 6.5839 11.2897 5.9812 7.5660 11.1269
Pan troglodytes 4 0.0308 0.0343 0.0000 4.1074 6.1913 6.5073 6.8595 11.7498 6.3998 7.7204 11.2448
Nomascus leucogenys 5 0.0006 0.0003 0.0001 0.0000 5.0211 5.2298 5.7693 10.8395 5.2982 7.1070 10.8292
Macaca mulatta 6 0.0000 0.0000 0.0000 0.0000 0.0000 1.1536 3.6155 11.1767 3.6094 6.9410 11.0363
Macaca fascicularis 7 0.0000 0.0000 0.0000 0.0000 0.0000 0.1255 3.8413 11.4172 3.8620 7.2260 11.1459
Papio anubis 8 0.0000 0.0000 0.0000 0.0000 0.0000 0.0002 0.0001 11.6141 3.8907 7.3265 11.4114
Tarsius syrichta 9 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 11.0365 10.9746 11.9989
Chlorocebus sabaeus 10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0002 0.0001 0.0001 0.0000 6.9330 11.0954
Saimiri boliviensis 11 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 10.9440
Otolemur garnettii 12 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
1 2 3 4 5 6 7 8 9 10 11 12
Homo sapiens 1 -1.3274 -4.2472 -1.8871 -3.2994 -5.5268 -5.8634 -6.2358 -11.4481 -5.8279 -7.2380 -11.1601
Gorilla gorilla 2 1.0000 -4.2148 -1.8369 -3.5671 -5.4446 -5.7682 -6.2115 -10.7631 -5.9708 -7.3304 -10.7901
Pongo abelii 3 1.0000 1.0000 -4.8435 -3.7643 -5.8965 -6.0396 -6.5839 -11.2897 -5.9812 -7.5660 -11.1269
Pan troglodytes 4 1.0000 1.0000 1.0000 -4.1074 -6.1913 -6.5073 -6.8595 -11.7498 -6.3998 -7.7204 -11.2448
Nomascus leucogenys 5 1.0000 1.0000 1.0000 1.0000 -5.0211 -5.2298 -5.7693 -10.8395 -5.2982 -7.1070 -10.8292
Macaca mulatta 6 1.0000 1.0000 1.0000 1.0000 1.0000 -1.1536 -3.6155 -11.1767 -3.6094 -6.9410 -11.0363
Macaca fascicularis 7 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -3.8413 -11.4172 -3.8620 -7.2260 -11.1459
Papio anubis 8 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -11.6141 -3.8907 -7.3265 -11.4114
Tarsius syrichta 9 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -11.0365 -10.9746 -11.9989
Chlorocebus sabaeus 10 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -6.9330 -11.0954
Saimiri boliviensis 11 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 -10.9440
Otolemur garnettii 12 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
Neutrality
Purifying
Positive
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Appendix 5:  In silico analysis of human and primate- and hominid-ancestral MERTK 
transmembrane domains. A)  Predicted transmembrane domains of human (red), hominid 
(orange) and primate (yellow) MERTK were modeled using Phyre2. Hyrdophobic residues are 
represented as sticks. B) Transmembrane secondary structure predictions for human, hominid and 
primate MERTK sequences. All sequences were analyzed using PSPRED.  The relative 
confidence of secondary structure prediction is shown in blue bars. Highlighted residues 
correspond to the modelled helices in (A). C) A hydrophobic cluster analysis was conducted for 
the MERTK transmembrane domains.  Hydrophobic residues are boxed, and non-hydrophobics 
are shown as diamonds and squares. 
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Appendix 6: Letter of permission for inclusion of appendix 5 in thesis. 
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